

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 May 2005 (06.05.2005)

PCT

(10) International Publication Number
WO 2005/040151 A1

(51) International Patent Classification⁷: C07D 401/04,
401/14, 409/14, 405/14, A61K 31/4965

(74) Agent: TABUSHI, Eiji; c/o Fujisawa Pharmaceutical
Co., Ltd., Osaki Factory, 1-6, Kashima 2-chome,, Yo-
dogawa-ku, Osaka-shi, OSAKA 532-8514 (JP).

(21) International Application Number:
PCT/JP2004/016193

(22) International Filing Date: 25 October 2004 (25.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2003905895 27 October 2003 (27.10.2003) AU
2004902764 24 May 2004 (24.05.2004) AU

(71) Applicant (for all designated States except US): FUJI-
SAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7,
Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-
8514 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YONISHI, Satoshi
[JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7,
Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka
541-8514 (JP). AOKI, Satoshi [JP/JP]; c/o Fujisawa Phar-
maceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku,
Osaka-shi, Osaka 541-8514 (JP). MATSUSHIMA,
Yuji [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd.,
4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka
541-8514 (JP). AKAHANE, Atsushi [JP/JP]; c/o Fuji-
sawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome,
Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF



(57) Abstract: A pyrazine derivative of the following formula (I): or a salt thereof. The pyrazine compound (I) and a salt thereof of the present invention are adeno-
sine antagonists and are useful for the prevention and/or treatment of depression,
dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompa-
nying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular
disease (e.g. stroke), etc.), heart failure and the like.

WO 2005/040151 A1

DESCRIPTION

PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF

TECHNICAL FIELD

The present invention relates to a novel pyrazine
5 derivative and a salt thereof, which are useful as
medicaments.


BACKGROUND ART

Adenosine is a ubiquitous biochemical messenger.
Adenosine binds to and activates seven-transmembrane
10 spanning G-protein coupled receptors, eliciting a variety
of physiological responses. Adenosine receptors are
divided into four known subtypes (i.e., A₁, A_{2a}, A_{2b}, and
A₃). These receptor subtypes mediate different, and
sometimes opposing, effects. Activation of the adenosine
15 A₁ receptor, for example, elicits an increase in renal
vascular resistance, while activation of the adenosine A_{2a}
receptor elicits a decrease in renal vascular resistance.
Accordingly, adenosine antagonists are useful in the
prevention and/or treatment of numerous diseases,
20 including cardiac and circulatory disorders, degenerative
disorders of the central nervous system, respiratory
disorders, and many diseases for which diuretic treatment
is suitable.

Some 2-aminopyridine compounds to exhibit adenosine
25 receptor antagonism are known (WO 02/14282, WO 01/25210,

etc.), and some 2-aminopyrimidine compounds are also known (US 2001/0027196, etc.).

However, it is generally difficult to produce a pyrazine which is substituted by four different substituents, and for example the synthesis of a pyrazine compound of the formula A :



wherein Ar and Ar' are independently same or different aryl; and

R, R' and M are independently hydrogen or suitable substituent;

is reported (e.g. (1) *J. Org. Chem.*, **40**, 2341 (1975) ., (2) *J. Heterocyclic Chem.*, **15**, 665 (1978), (3) *J. Chem. Soc., Perkin Trans. 1*, 885 (1994) ., (4) *Synthesis*, 931 (1994) ., (5) WO-02/088084, etc.), however the Ar and Ar' thereof are same, and the selective synthesis of a pyrazine compound A wherein Ar and Ar' are different is not shown as far as we know, and 2-amino-6-aryl-5-(6-oxo-1,6-dihydro-pyrid-3-yl)-pyrazine compounds and derivatives thereof are novel, so there has been no knowledge about these compounds, so far. In addition, any pyrazine derivatives having both of adenosine A₁ and A_{2a} inhibitory activities are not known.

DISCLOSURE OF INVENTION

The present invention relates to a novel pyrazine derivative and a pharmaceutically acceptable salt thereof, which are useful as medicaments with no or less toxicity (particularly the convulsive toxicity); processes for preparing the preparation of pyrazine derivative and a salt thereof; a pharmaceutical composition comprising, as an active ingredient, said pyrazine derivative or a pharmaceutically acceptable salt thereof; a use of said pyrazine derivative or a pharmaceutically acceptable salt thereof as a medicament; and a method for using said pyrazine derivative or a pharmaceutically acceptable salt thereof for therapeutic purposes, which comprises administering said pyrazine derivative or a pharmaceutically acceptable salt thereof to a human being or an animal.

The pyrazine derivatives and a salt thereof are adenosine antagonists (especially, A_1 receptor and A_2 (particularly A_{2a}) receptor dual antagonists) and possess various pharmacological actions such as anticatalepsy action, cognitive enhancing action, analgesic action, locomotor action, antidepressant action, diuretic action, cardioprotective action, cardiotonic action, vasodilating action (e.g. cerebral vasodilating action, etc.), the action of increasing the renal blood flow, renal protective

action, improvement action of renal function, enhancing
action of lipolysis, inhibition action of anaphylactic
bronchoconstriction, acceleration action of the insulin
release, the action of increasing the production of
5 erythropoietin, inhibiting action of platelet aggregation,
or the like.

They are useful as cognitive enhancer, antianxiety
drug, antidementia drug, psychostimulant, analgesic,
cardioprotective agent, antidepressant, ameliorants of
10 cerebral circulation, tranquilizer, drug for heart failure,
cardiotonic agent, antihypertensive agent, drug for renal
failure (renal insufficiency), drug for renal toxicity,
renal protective agent, drug for improvement of renal
function, diuretic, drug for edema, antiobesity,
15 antiasthmatic, bronchodilator, drug for apnea, drug for
gout, drug for hyperuricemia, drug for sudden infant death
syndrome (SIDS), ameliorants of immunosuppressive action
of adenosine, antidiabetic agent, drug for ulcer, drug for
pancreatitis, drug for Meniere's syndrome, drug for anemia;
20 drug for thrombosis, drug for myocardial infarction, drug
for obstruction, drug for arteriosclerosis obliterans,
drug for thrombophlebitis, drug for cerebral infarction,
drug for transient ischemic attack, drug for angina
pectoris, or the like; and useful for the prevention and/or
25 treatment of depression, dementia (e.g. Alzheimer's


disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure; hypertension (e.g. essential hypertension, nephrogenous hypertension, etc.); circulatory insufficiency (acute circulatory insufficiency) caused by, for example, ischemia/reperfusion injury (e.g. myocardial ischemia/reperfusion injury, cerebral ischemia/reperfusion injury, peripheral ischemia/reperfusion injury, etc.), shock (e.g. endotoxin shock, hemorrhagic shock, etc.), surgical procedure, or the like; post-resuscitation asystole; bradyarrhythmia; electro-mechanical dissociation; hemodynamic collapse; SIRS (systemic inflammatory response syndrome); multiple organ failure; renal failure (renal insufficiency) (e.g. acute renal failure, etc.), renal toxicity [e.g. renal toxicity induced by a drug such as cisplatin, gentamicin, FR-900506 (disclosed in EP-0184162), cyclosporin (e.g. cyclosporin A) or the like; glycerol, etc.], nephrosis, nephritis, edema (e.g. cardiac edema, nephrotic edema, hepatic edema, idiopathic edema, drug edema, acute angioneurotic edema, hereditary angioneurotic edema, carcinomatous ascites, gestational edema, etc.); obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer such as

peptic ulcer (e.g. gastric ulcer, duodenal ulcer, etc.),
 pancreatitis, Meniere's syndrome, anemia,
 dialysis-induced hypotension, constipation, ischemic
 bowel disease, ileus (e.g. mechanical ileus, adynamic ileus,
 5 etc.); and myocardial infarction, thrombosis (e.g.
 arterial thrombosis, cerebral thrombosis, etc.),
 obstruction, arteriosclerosis obliterans,
 thrombophlebitis, cerebral infarction, transient ischemic
 attack, angina pectoris, or the like.


10

The novel pyrazine derivative or a salt thereof of
 the present invention can be shown by the following formula
 (I):

15



wherein



20

wherein

R⁶ is hydrogen, or optionally substituted lower
 alkyl;

R⁷ is hydrogen or halogen;

25 R⁸ is lower alkyl;

R^2 is hydrogen; hydroxy; halogen; cyano; or lower alkyl,
 lower alkenyl, lower alkynyl, lower alkoxy, aryloxy,
 arylthio, acyl, aryl, heterocyclic group or amino,
 each of which is optionally substituted by
 5 substituent(s);


R^3 and R^4 are independently hydrogen, lower alkyl or acyl;
 and

R^5 is lower alkyl, lower alkenyl, lower alkynyl, cyano,
 aryl or heterocyclic group, each of which is
 10 optionally substituted by substituent(s);
 or a salt thereof.

The preferred embodiments of the pyrazine compound
 of the present invention represented by the general formula

15 (I) are as follows.

(1) The pyrazine compound of the general formula (I)
 wherein



wherein

R^6 is hydrogen, lower alkyl, aryl(lower)alkyl,
 heteroaryl(lower)alkyl;

R^7 is hydrogen or halogen;

25 R^2 is hydrogen, halogen, cyano, optionally substituted

lower alkyl, optionally substituted lower alkynyl,
lower alkoxy, aryloxy, arylthio, carbamoyl,
carboxy, protected carboxy or optionally
substituted amino;

5 R^3 and R^4 are independently hydrogen or lower alkyl;
and

R^5 is aryl or heteroaryl each of which is optionally
substituted by one or more substituent(s);
or a salt thereof.

10 (2) The pyrazine compound of (1) above
wherein

R^2 is hydrogen, halogen, cyano,
hydroxylated(lower)alkyl, lower alkynyl, lower
alkoxy, aryloxy, arylthio, carboxy, esterified
15 carboxy, carbamoyl, amidated carboxy, amino or
mono- or di-(lower)alkylamino;

R^3 and R^4 are independently hydrogen;

R^5 is aryl or heteroaryl, each of which is optionally
substituted by one or more substituent(s) selected
20 from the group consisting of halogen and lower
alkoxy;

R^6 is hydrogen or lower alkyl; and

R^7 is hydrogen;

or a salt thereof.

25 (3) The pyrazine compound of (2) above

wherein

R² is hydrogen, bromo, cyano, hydroxymethyl,
hydroxyethyl, hydroxypropyl, ethynyl, methoxy,
ethoxy, propoxy, phényloxy, phenylthio, carboxy,
5 carbamoyl, mono- or di-methylaminocarbonyl,
pyridylmethylaminocarbonyl,
hydroxymethylaminocarbonyl or mono- or
di-methylamino;

R³ and R⁴ are independently hydrogen;

10 R⁵ is phenyl, pyridyl, furyl, thienyl, pyrrolyl or
pyrazolyl, each of which is optionally substituted
by one or more substituent(s) selected from the
group consisting of fluoro, chloro and methoxy;

R⁶ is hydrogen, methyl, ethyl, n-propyl, isopropyl,
15 n-butyl or t-butyl ; and

R⁷ is hydrogen;

or a salt thereof.

(4) The pyrazine compound of (3) above

wherein

20 R² is hydrogen, cyano, ethynyl, methoxy, phenyloxy,
phenylthio, carboxy, carbamoyl or methylamino;
and

R⁵ is phenyl, furyl or thienyl, each of which is
optionally substituted by one or more
25 substituent(s) selected from the group consisting

of fluoro, chloro and methoxy;

or a salt thereof.

(5) The pyrazine compound of (4) above

wherein

5 R^2 is hydrogen, cyano, carboxy, carbamoyl or
methylamino;


R^5 is phenyl which is optionally substituted by one or
more fluoro; and

R^6 is hydrogen, methyl, ethyl or isopropyl;

10 or a salt thereof.


The object compound (I) and a salt thereof of the
present invention can be prepared by the following
processes.

15 Process 1







20 or a salt thereof or a salt thereof or a salt thereof

Process 2



or a salt thereof

or a salt thereof

Process 3Process 4Process 5Process 6

30

Process 7




(If)

(Ih)

or a salt thereof

or a salt thereof

Process 8



(Ih)

(Ij)

or a salt thereof

or a salt thereof

(V)

or a salt thereof

[wherein R¹, R², R³, R⁴, R⁵ and R⁶ are each as defined above;

R⁹ is cyano, carbamoyl or carboxy;

R¹⁰ is optionally substituted lower alkyl;

20 R¹¹ and R¹² are independently hydrogen, lower alkyl, lower
alkoxy or cyclo(lower)alkyl, each of which
is optionally substituted by
substituent(s); or R¹¹ and R¹², together
with the nitrogen atom to which they are
25 attached, represent a optionally
substituted N-containing heterocyclic
group;

R¹³ is lower alkyl, lower alkenyl, lower alkynyl,

lower alkoxy, aryloxy, arylthio, acyl, aryl,
heterocyclic group or amino, each of which is
optionally substituted by substituent(s);

Y is a leaving group;

5 Hal is a halogen atom; and

Z is hydrogen, an alkali metal (e.g. lithium, sodium,
potassium, etc.), SnBu_3 , BW_2 or Met-Hal;

wherein BW_2 is a part of organoboron compound such as

B(OH)_2 , $\text{B(CH}_2\text{CH}_2\text{CH(CH}_3)_2)_2$,

10 tetramethyl-1,3,2-dioxaborolan-2-yl,

9-borabicyclo[3.3.1]nonanyl, or the like;


and


Met-Hal is a part of metalhalide compound such
as MgBr , ZnCl , or the like.]

15


The starting compounds or a salt thereof can be
prepared, for example, by the following reaction schemes.

Process A



Process B


5 or a salt thereof or a salt thereof or a salt thereof

Process C

10

or a salt thereof

or a salt thereof


Process D

15

20

or a salt thereof

or a salt thereof

Process E

25

or a salt thereof

or a salt thereof

or a salt thereof

30 [wherein R¹, R², R³, R⁴, R¹⁰, Y and Hal are each as defined

above.]

In addition to the processes as mentioned above, the object compound (I) and a salt thereof can be prepared, for example, according to the procedures as illustrated in Examples in the present specification or in a manner similar thereto.

The starting compounds can be prepared, for example, according to the procedures as illustrated in Preparations in the present specification or in a manner similar thereto.

The object compound (I) and a salt thereof can be prepared according to the methods as shown in Preparations or Examples, or in a manner similar thereto.

It is also to be noted that the solvating form of the compound (I) (e.g. hydrate, etc.) and any form of the crystal of the compound (I) are included within the scope of the present invention.

It is also to be noted that radiolabelled derivatives of the compound (I), which are suitable for biological studies, are included within the scope of the present invention.

Suitable salts of the object compound (I) are conventional pharmaceutically acceptable ones and include a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g.

calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.), an organic acid salt (e.g. acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc.), an inorganic acid salt (e.g. hydrochloride, hydrobromide, hydriodide, sulfate, phosphate, etc.), a salt with an amino acid (e.g. arginine, aspartic acid, glutamic acid, etc.), and the like.

Suitable examples and illustrations of the various definitions which the present invention includes within the scope thereof and which appear in the above and following description in the present specification are explained in detail as follows.

The term "optionally substituted" refers to "unsubstituted or substituted".

The term "lower" is intended to mean 1 to 6 carbon atom(s) unless otherwise indicated.

Suitable "lower alkyl" and "(lower)alkyl" moiety in the term of "mono- or di-(lower)alkylamino" may include straight or branched ones such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl or the like, in which the preferred one may be methyl, ethyl or isopropyl.

Suitable "optionally substituted lower alkyl" may include lower alkyl which is optionally substituted by suitable substituent(s) such as lower alkoxy, hydroxy, aryloxy, cyclo(lower)alkyl, amino, aryl, heterocyclic group, acyl or the like.

Suitable "lower alkoxy" may include straight or branched ones such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy or the like.

Suitable "optionally substituted lower alkoxy" may include lower alkoxy which is optionally substituted by suitable substituent(s) such as hydroxy, cyclo(lower)alkyl, amino, aryl, heterocyclic group, acyl or the like.

Suitable "cyclo(lower)alkyl" may be cyclo(C3-C8)alkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or the like, in which the preferred one may be cyclohexyl.

Suitable "lower alkenyl" may include straight or branched ones such as vinyl, propenyl, allyl, isopropenyl, butenyl, pentenyl, hexenyl or the like, in which the preferred one may be vinyl.

Suitable "optionally substituted lower alkenyl" may include lower alkenyl which is optionally substituted by suitable substituent(s) such as lower alkoxy, hydroxy, cyclo(lower)alkyl, amino, aryl, heterocyclic group, acyl or the like.

Suitable "lower alkynyl" may include straight or branched ones such as ethynyl, propynyl, butynyl, pentynyl, hexynyl or the like, in which the preferred one may be ethynyl.

5 Suitable "optionally substituted lower alkynyl" may include lower alkynyl which is optionally substituted by suitable substituent(s) such as lower alkoxy, hydroxy, cyclo(lower)alkyl, amino, aryl, heterocyclic group, acyl or the like.

10 Suitable "aryl" and "aryl" moiety in the term of "aryloxy" or "arylthio" may include phenyl, naphthyl, indenyl, anthryl, or the like, in which the preferred one may be (C6-C10) aryl, and the more preferred one may be phenyl.

15 Suitable "aryl(lower)alkyl" may include phenyl(lower)alkyl (e.g. benzyl, phenethyl, etc.), diphenyl(lower)alkyl (e.g. benzhydryl, etc.), triphenyl(lower)alkyl (e.g. trityl, etc.), naphthyl(lower)alkyl, indenyl(lower)alkyl or
20 anthryl(lower)alkyl and the like, in which the preferred one may be phenyl(lower)alkyl, and the more preferred one may be phenyl(C1-C4)alkyl.

 Suitable "optionally substituted aryl" may include aryl which is optionally substituted by suitable
25 substituent(s), preferably 1 to 3 substituent(s), such as

lower alkyl, lower alkoxy, hydroxy, halogen, etc. Suitable examples of optionally substituted aryl include lower alkylphenyl, lower alkoxyphenyl and halophenyl.

Suitable "heterocyclic group" may be saturated or
5 unsaturated monocyclic or polycyclic heterocyclic groups containing at least one heteroatom selected from among oxygen, sulfur and nitrogen.

The particularly preferred example of said heterocyclic group may include

10 3- through 8-membered unsaturated heteromonocyclic groups containing 1 through 4 nitrogen atom(s), such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl and its N-oxide, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl,
15 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), dihydrotriazinyl (e.g. 4,5-dihydro-1,2,4-triazinyl, 2,5-dihydro-1,2,4-triazinyl, etc.), etc.;

3- through 8-membered saturated heteromonocyclic
20 groups containing 1 through 4 nitrogen atom(s), such as azetidiny, pyrrolidinyl, imidazolidinyl, piperidyl (e.g. piperidino, etc.), piperazinyl, etc.;

unsaturated condensed heterocyclic groups containing 1 through 5 nitrogen atom(s), such as indolyl,
25 isoindolyl, indolizinyl, benzimidazolyl, quinolyl,

isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridyl, tetrazolopyridazinyl (e.g. tetrazolo[1,5-b]pyridazinyl etc.), dihydrotriazolopyridazinyl, etc.;

3- through 8-membered unsaturated heteromonocyclic groups containing 1 or 2 oxygen atoms and 1 through 3 nitrogen atom(s), such as oxazolyl, isoxazolyl, oxadiazolyl (e.g. 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.), etc.;

3- through 8-membered saturated heteromonocyclic groups containing 1 or 2 oxygen atom(s) and 1 through 3 nitrogen atoms, such as morpholinyl, oxazolidinyl (e.g. 1,3-oxazolidinyl etc.), etc.;

unsaturated condensed heterocyclic groups containing 1 or 2 oxygen atom(s) and 1 through 3 nitrogen atom(s), such as benzoxazolyl, benzoxadiazolyl, etc.;

3- through 8-membered unsaturated heteromonocyclic groups containing 1 or 2 sulfur atom(s) and 1 through 3 nitrogen atom(s), such as thiazolyl, isothiazolyl, thiazolinyl, thiadiazolyl (e.g. 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,2,3-thiadiazolyl), etc.;

3- through 8-membered saturated heteromonocyclic groups containing 1 or 2 sulfur atom(s) and 1 through 3 nitrogen atom(s), such as thiazolidinyl etc.;

3- through 8-membered unsaturated heteromonocyclic

groups containing 1 sulfur atom, such as thienyl etc.;

unsaturated condensed heterocyclic groups

containing 1 or 2 sulfur atoms and 1 through 3 nitrogen atom(s), such as benzothiazolyl, benzothiadiazolyl, etc.;

5 3- through 8-membered unsaturated heteromonocyclic groups containing 1 or 2 oxygen atom(s), such as furyl, pyranyl, dioxolyl, etc.;

3- through 8-membered saturated heteromonocyclic groups containing 1 or 2 oxygen atom(s), such as oxolanyl, tetrahydropyranyl (e.g. tetrahydro-2H-pyran-2-yl etc.),
10 dioxolanyl, etc.; and

unsaturated condensed heterocyclic groups containing 1 or 2 oxygen atom(s), such as isobenzofuranyl, chromenyl (e.g. 2H-chromen-3-yl etc.), dihydrochromenyl
15 (e.g. 3,4-dihydro-2H-chromen-4-yl etc.), etc.

Suitable "optionally substituted heterocyclic group" may include heterocyclic group which is optionally substituted by suitable substituent(s), preferably 1 to 3 substituent(s), such as lower alkyl, lower alkoxy, hydroxy,
20 halogen, or the like.

Suitable "N-containing heterocyclic group" may be aforesaid "heterocyclic group", in which said group contains at least one N atom in its ring members, such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, triazolyl,
25 tetrazolyl, dihydrotriazinyl, azetidiny, pyrrolidinyl,

imidazolidinyl, piperidyl, piperazinyl, indolyl,
isoindolyl, indazolyl, benzotriazolyl,
dihydrotriazolopyridazinyl, morpholinyl, oxazolidinyl,
thiazolynyl, thiazolidinyl, etc.

5 Suitable "heteroaryl" and "heteroaryl" moiety in the
term of "heteroaryl(lower)alkyl" may be aforesaid
"heterocyclic group", in which those categorized as an
aromatic heterocyclic group, such as pyrrolyl, pyrrolinyl,
imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl,
10 pyridazinyl, triazolyl, tetrazolyl, dihydrotriazinyl,
indolyl, isoindolyl, indolizinyl, benzimidazolyl,
quinolyl, isoquinolyl, indazolyl, benzotriazolyl,
tetrazolopyridyl, tetrazolopyridazinyl,
dihydrotriazolopyridazinyl, oxazolyl, isoxazolyl,
15 oxadiazolyl, benzoxazolyl, benzoxadiazolyl, thiazolyl,
isothiazolyl, thiazolinyl, thiadiazolyl, thienyl,
benzothiazolyl, benzothiadiazolyl, furyl, pyranyl,
dioxolyl, isobenzofuranyl, chromenyl, dihydrochromenyl,
etc.

20 Suitable "acyl" may include lower alkanoyl, aroyl,
carboxy, protected carboxy, and the like.

Suitable examples of aforesaid "lower alkanoyl" may
be formyl, acetyl, propionyl, butyryl, isobutyryl,
pivaloyl, hexanoyl, or the like, in which the preferred one
25 may be (C1-C4)alkanoyl.

Suitable examples of aforesaid "aroyl" may be benzoyl, toluoyl, or the like.

Suitable examples of aforesaid "protected carboxy" may be

- 5 i) esterified carboxy, in which suitable esterified carboxy may include lower alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, t-butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, etc.), aryl(lower)alkoxycarbonyl (e.g. 10 benzyloxycarbonyl, phenethyloxycarbonyl, 2-phenylpropoxycarbonyl, 4-phenylbutoxycarbonyl, 4-phenylpentyloxycarbonyl, 1,3-diphenylhexyloxycarbonyl, etc.), and the like;
- ii) amidated carboxy, in which suitable amidated 15 carboxy may include carbamoyl, N-(lower)alkylcarbamoyl (e.g. N-methylcarbamoyl, N-ethylcarbamoyl, N-isopropylcarbamoyl, N-butylcarbamoyl, N-pentylcarbamoyl, N-hexylcarbamoyl, etc.), N,N-di(lower)alkylcarbamoyl [e.g. N,N-dimethylcarbamoyl, 20 N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, N,N-dipropylcarbamoyl, N,N-di(t-butyl)carbamoyl, N-pentyl-N-hexylcarbamoyl, etc.], N-lower alkyl-N-aryl(lower)alkylcarbamoyl (e.g. N-methyl-N-benzylcarbamoyl, etc), and the like.

- 25 Suitable "halogen" may be fluoro, chloro, bromo and

iodo.

Suitable "a leaving group" may include halogen, hydroxy, acyloxy such as alkanoyloxy (e.g. acetoxy, propionyloxy, etc.) or sulfonyloxy (e.g. mesyloxy, tosyloxy, etc.), or the like.

Suitable "optionally substituted amino" may include amino, mono- or di-(lower)alkylamino (e.g. methylamino, dimethylamino, methylethylamino, etc.), acylamino (e.g. lower alkoxy-carbonylamino (e.g. methoxycarbonylamino, ethoxycarbonylamino, etc.), sulfonylamino (e.g. mesylamino, etc.), ureido, etc.), or the like.

The processes for preparing the object pyrazine compound (I) are explained in detail in the following.

15

Process 1

The compound (I) or a salt thereof can be prepared by subjecting the compound (II) or a salt thereof to coupling reaction with the compound (III) or a salt thereof.

20

This reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, 1,2-dimethoxyethane, chloroform, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, methanol, ethanol, diethyl ether, 1,3-dimethyl-2-imidazolidinone,

25

N-methylpyrrolidone, N,N'-dimethylpropyleneurea, a mixture thereof or any other organic solvent which does not adversely affect the reaction.

Some of the present reaction is preferably carried out in the presence of an organic or inorganic base such as an alkali metal (e.g. sodium, potassium, etc.), an alkaline earth metal (e.g. magnesium, calcium, etc.), the hydride or hydroxide or alkoxide or carbonate or hydrogencarbonate or alkanoic acid thereof, trialkylamine (e.g. triethylamine, trimethylamine, etc.), hydrazine, pyridine compound (e.g. pyridine, lutidine, picoline, 4-dimethylaminopyridine, etc.), quinoline, and the like.

Some of the present reaction is preferably carried out in the presence of a catalyst such as palladium(II) acetate, tetrakis(triphenylphosphine) palladium(0), and the like.

The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature, under warming or heating.

20 Process 2

The compound (Iba) or a salt thereof can be prepared by subjecting the compound (Ia) or a salt thereof to hydrolysis.

This reaction is carried out in accordance with a conventional method.

The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

Suitable base includes an inorganic base and an organic base such as an alkali metal (e.g. sodium, potassium, etc.), an alkaline earth metal (e.g. magnesium, calcium, etc.), the hydroxide or carbonate or hydrogencarbonate thereof, trialkylamine (e.g. triethylamine, trimethylamine, etc.), hydrazine, pyridine compound (e.g. pyridine, lutidine, picoline, 4-dimethylaminopyridine, etc.), 1,5-diazabicyclo[4.3.0]non-5-ene, quinoline, 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene, or the like.

Suitable acid includes an organic acid (e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.) and an inorganic acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.).

The elimination using Lewis acid such as boron tribromide, boron trichloride, boron trifluoride, aluminum chloride or the like is preferably carried out in the presence of cation trapping agents (e.g. anisole, phenol, etc.).

The hydrolysis in this case usually carried out in the presence of an acid including Lewis acid, and these acid(s) including Lewis acid(s) can be used in the mixture,

and the point(s) or the number of being hydrolyzed can be different by the condition (see the example part (examples 2, 7, 10 and 15) in detail).

The reaction is usually carried out in a solvent such as water, an alcohol (e.g. methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, dichloromethane, 1,2-dichloroethane, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide, or any other organic solvent which does not adversely affect the reaction, or a mixture thereof.

A liquid base or acid can be also used as the solvent.

The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.

Process 3

The compound (Ic) or a salt thereof can be prepared by subjecting the compound (Ib) or a salt thereof to the alkylation with the compound (IV) or a salt thereof.

Suitable salt of the compound (IV) can be referred ones as exemplified for the compound (I).

This reaction is carried out in a solvent such as water, phosphate buffer, acetone, chloroform, acetonitrile, nitrobenzene, dichloromethane, 1,2-dichloroethane, formamide, N,N-dimethylformamide, methanol, ethanol, sec-butanol, amyl alcohol, diethyl ether, dioxane, 1,2-dimethoxyethane, tetrahydrofuran, dimethyl sulfoxide,

or any other organic solvent which does not adversely affect the reaction, preferably in ones having strong polarities. Among the solvents, hydrophilic solvents may be used in a mixture with water. When the compound (IV) is in a liquid state, it can also be used as a solvent. The reaction is preferably conducted in the presence of a base, for example, inorganic base such as alkali metal hydroxide, alkali metal alkoxide (e.g. potassium *t*-butoxide), alkali metal carbonate, alkali metal bicarbonate, alkali metal hydride (e.g. sodium hydride, etc.), or organic base such as trialkylamine (e.g. triethylamine, etc.), or basic resin, and the like.

The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature, under warming or heating.

The present reaction is preferably carried out in the presence of alkali metal halide (e.g. sodium iodide, potassium iodide, etc.), or the like.

When Y is -OH, activation of OH with triphenylphosphine, or the like, and di (lower) alkyl azodicarboxylate (e.g. diethyl azodicarboxylate, diisopropyl azodicarboxylate, etc.), or the like, may be necessary.

Process 4

The compound (Ie) or a salt thereof can be prepared

by subjecting the compound (Id) or a salt thereof to hydrolysis using a base or an acid.

This reaction can be carried out in the same manner as the aforementioned hydrolysis using a base in Process 2, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 2.

Process 5

The compound (If) or a salt thereof can be prepared by decarboxylation of the compound (Ie) or a salt thereof.

This reaction is carried out in accordance with a conventional method such as thermal decomposition, acid decomposition and the like; more suitable one in this case is thermal decomposition.

The reaction is usually carried out in a conventional inactive solvent such as quinoline, dichlorobenzene, mesitylene, dodecane, Dowtherm® (phenyl ether-biphenyl eutectic mixture) or any other organic solvent which does not adversely affect the reaction, or a mixture thereof; more suitable one in this case is 1,2-dichlorobenzene.

The reaction temperature is not critical, and the reaction is usually carried out on 100°C-200°C heating condition.

Process 6

The compound (Ig) or a salt thereof can be prepared

by amidation of the compound (Ie) or a salt thereof.

The reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely affect the reaction, or a mixture thereof.

The reaction is preferably carried out in the presence of a conventional condensing agent such as

10 N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethyl-carbodiimide; N-cyclohexyl-N'-(4-diethylaminocyclohexyl)-carbodiimide; N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; N,N-carbonyl-bis-(2-methylimidazole); pentamethyleneketene-

15 N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkyl phosphite; isopropyl polyphosphate; phosphorus oxychloride (phosphoryl chloride); phosphorus

20 trichloride; thionyl chloride; oxalyl chloride; triphenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(*m*-sulfophenyl)isoxazolium hydroxide intramolecular salt; 1-(*p*-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; so-called Vilsmeier reagent

25 prepared by the reaction of N,N-dimethylformamide with

thionyl chloride, phosgene, phosphorus oxychloride, etc.;
or the like.

The reaction may also be carried out in the presence
of an organic or inorganic base such as an alkali metal
5 bicarbonate, tri(lower)alkylamine, pyridine, N-(lower)-
alkylmorpholine, N,N-di(lower)alkylbenzylamine, or the
like.

The reaction temperature is not critical, and the
reaction is usually carried out under cooling to heating.

10 Process 7

The compound (Ih) or a salt thereof can be prepared
by subjecting the compound (If) or a salt thereof to
halogenation with a halogenating agent such as
N-halosuccinimide (e.g. N-chlorosuccinimide,
15 N-bromosuccinimide, etc.), or the like.

The reaction is usually carried out in a solvent such
as tetrahydrofuran, dioxane, toluene, dichloromethane,
1,2-dichloroethane, chloroform, N,N-dimethylformamide,
N,N-dimethylacetamide, or any other organic solvent which
20 does not adversely affect the reaction, or a mixture
thereof.

Process 8

The compound (Ij) or a salt thereof can be prepared
by subjecting the compound (Ih) or a salt thereof to
25 coupling reaction with the compound (V) or a salt thereof.

This reaction can be carried out in the same manner as the aforementioned coupling reaction in Process 1, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 1.

Process A

The compound (VII) or a salt thereof can be prepared by subjecting the compound (VI) or a salt thereof to hydrolysis using an acid (exemplified by Step 1). This reaction can be carried out in the same manner as the aforementioned hydrolysis using an acid in Process 2, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 2.

And the object compound (VIII) can be prepared by subjecting the compound (VII) or a salt thereof to the alkylation with the compound (IV) or a salt thereof (exemplified by Step 2). This reaction can be carried out in the same manner as in the aforementioned Process 3, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 3.

Process B

The compound (X) or a salt thereof can be prepared from the acetylation of the compound (IX) (exemplified by

Step 1) by the methods disclosed in Preparation 1 mentioned later or the similar manner thereto.

And the object compound (XI) can be prepared by subjecting the compound (X) to the oxime-formation reaction
5 (exemplified by Step 2) that disclosed in Preparation 2 mentioned later or the similar manners thereto.

Process C

The compound (XII) or a salt thereof can be prepared by reacting the compound (XI) or a salt thereof with
10 aminomalonitrile or a salt thereof.

The present reaction is preferably carried out in the presence of a catalyst such as *p*-toluenesulfonic acid, and the like.

This reaction is usually carried out in a
15 conventional solvent such as water, acetone, dioxane, acetonitrile, 1,2-dimethoxyethane, chloroform, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, ethyl acetate, *N,N*-dimethylformamide, methanol, ethanol, isopropanol, *t*-butanol, diethyl ether, isopropyl ether, a
20 mixture thereof or any other organic solvent which does not adversely affect the reaction.

The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature, under warming or heating.

25 This reaction can be carried out by the method

disclosed in Preparation 3 mentioned later or the similar manner thereto.

Process D

The compound (XVI) or a salt thereof can be prepared by subjecting the compound (XIII) or a salt thereof to hydrolysis using an acid.

Process E

The compound (II) or a salt thereof can be prepared by reacting the compound (XV) or a salt thereof with the compound (XVI) or a salt thereof.

This reaction is usually carried out in a conventional solvent such as acetone, dioxane, acetonitrile, 1,2-dimethoxyethane, chloroform, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, diethyl ether, isopropyl ether, a mixture thereof or any other organic solvent which does not adversely affect the reaction.

This reaction can be carried out by the method disclosed in Preparation 4 mentioned later or the similar manner thereto.

Above processes, all starting materials and product compounds may be salts. The compounds of above processes can be converted to salts according to a conventional method.

The object compound (I) of the present invention is an adenosine antagonist and possesses the various pharmacological actions as stated before.

5 In order to show the usefulness of the compound (I) of the present invention, the pharmacological test result of the representative compound of the present invention is shown in the following.

10 Test 1 : Adenosine antagonistic activity

[I] Test method

The adenosine antagonistic activity [K_i (nM)] of the test compound was examined by radioligand binding techniques using 8-cyclopentyl-1,3-dipropylxanthine,
15 [dipropyl-2,3- ^3H (N)] ([^3H]DPCPX, 4.5nM) for human A_1 receptor and [^3H]CGS 21680 (20nM) for human A_{2a} receptor.

[II] Test compound

3-Amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (Example 4)

20 3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (Example 11)

3-Amino-5-(3,4-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile (Example 39)

25 3-Amino-N-(cyanomethyl)-6-(1-isopropyl-6-oxo-

1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide
(Example 46)

5-[5-amino-6-(hydroxymethyl)-3-phenyl-
2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (Example 47)

5 3-Amino-N-(2-hydroxyethyl)-6-(1-isopropyl-6-oxo-
1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide
(Example 49)

5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-3-bromo-
1-isopropyl-2(1H)-pyridone (Example 53)

10 5-[5-Amino-3-(2-thienyl)-2-pyrazinyl]-1-isopropyl-
2(1H)-pyridone (Example 115)

5-[5-Amino-3-(3,5-difluorophenyl)-2-pyrazinyl]-1-
isopropyl-2(1H)-pyridone (Example 129)

15 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-
isopropyl-2(1H)-pyridone (Example 141)

5-[5-Amino-6-(2-furyl)-3-phenyl-2-pyrazinyl]-1-
isopropyl-2(1H)-pyridone (Example 144)

5-(5-amino-6-phenoxy-3-phenyl-2-pyrazinyl)-1-
isopropyl-2(1H)-pyridone (Example 151)

20

[III] Test result

Table 1

		Adenosine receptor binding	
Test compound		(K _i :nM)	
(Example No.)		A ₁	A _{2a}
	4	5.09	2.34
5	11	22.47	2.35
	39	23.99	6.52
	46	5.25	1.49
	47	22.27	7.52
	49	6.07	1.69
10	53	0.93	0.91
	115	4.89	0.84
	129	10.71	3.90
	141	0.61	0.23
	144	1.78	0.54
15	151	1.57	0.32

Test 2 : Anticatalepsy activity in Mouse

[I] Test method

The test compound (3.2mg/kg) was administered orally
 20 with ddY mice (n=7). Then, haloperidol (0.32mg/kg) was
 injected intraperitoneally 30 min. after the

administration of the compound. Thirty min. after the injection, the cataleptic responses of mice were measured. The forelimbs of each mouse were placed on a 3 cm high, 3 mm wide horizontal bar, and the duration of cataleptic posture was measured for up to 30 sec.

[II] Test compound

3-Amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (Example 4)

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (Example 11)

3-Amino-5-(3,4-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile (Example 39)

3-Amino-N-(cyanomethyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (Example 46)

5-[5-amino-6-(hydroxymethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (Example 47)

3-Amino-N-(2-hydroxyethyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (Example 49)

5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-3-bromo-1-isopropyl-2(1H)-pyridone (Example 53)

5-[5-Amino-3-(2-thienyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (Example 115)

5-[5-Amino-3-(3,5-difluorophenyl)-2-pyrazinyl]-1-
isopropyl-2(1H)-pyridone (Example 129)

5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-
isopropyl-2(1H)-pyridone (Example 141)

5 5-[5-Amino-6-(2-furyl)-3-phenyl-2-pyrazinyl]-1-
isopropyl-2(1H)-pyridone (Example 144)

5-(5-amino-6-phenoxy-3-phenyl-2-pyrazinyl)-1-
isopropyl-2(1H)-pyridone (Example 151)

10

15

20

25

[III] Test result

Table 2

Manifestation rate of	
Test compound	Catalepsy
(Example No.)	(number of mouse)
4	0/7
11	0/7
5 39	0/7
46	0/7
47	1/7
49	1/7
53	0/7
10 115	0/7
129	0/7
141	0/7
144	0/7
151	0/7

15

The pyrazine compound (I) and a salt thereof of this invention are useful as adenosine antagonists (especially, A₁ receptor and A₂ (particularly A_{2a}) receptor dual antagonists) and for the prevention and/or the treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying

Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease, heart failure, hypertension, circulatory insufficiency, post-resuscitation, asystole, bradyarrhythmia, electro-mechanical dissociation, hemodynamic collapse, SIRS (systemic inflammatory response syndrome), multiple organ failure, renal failure (renal insufficiency), renal toxicity, nephrosis, nephritis, edema, obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer, pancreatitis, Meniere's syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus, myocardial infarction, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack, angina pectoris, and the like.

Adenosine antagonists can be useful for Parkinson's disease by co-administrating with L-3,4-dihydroxy-phenylalanine (L-DOPA), which is the most popular drug for Parkinson's disease (R. Grondin et al., *Neurology*, 52, 1673 (1999)). So the combination use of the pyrazine compound (I) and a salt thereof of this invention with L-DOPA may be also useful for treatment and/or prevention of Parkinson's disease with decreasing or reducing the side effect such as the onset of dyskinesia eliciting by the long-term application of L-DOPA, and so

on.

Further, in view of the field using these compounds for as a medicament, these compounds should be durable to some degree. And the duration time of the pyrazine compound
5 (I) or a salt thereof of this invention are expected to be long-lasting.

The pharmaceutical composition of this invention can be used in the form of a pharmaceutical preparation, for example, in a solid, semisolid or liquid form, which
10 contains the pyrazine compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical), oral or parenteral
15 (including subcutaneous, intravenous and intramuscular) administrations or insufflation. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, troches, capsules, suppositories, creams, ointments,
20 aerosols, powders for insufflation, solutions, emulsions, suspensions, and any other form suitable for use. In addition, auxiliary, stabilizing agents, thickening agents, coloring agents and perfumes may be used where necessary. The pyrazine compound (I) or a pharmaceutically acceptable
25 salt thereof is included in a pharmaceutical composition

in an amount sufficient to produce the desired aforesaid pharmaceutical effect upon the process or condition of diseases.

For applying the composition to a human being or an animal, it is preferable to apply it by intravenous, intramuscular, pulmonary or oral administration, or insufflation. While the dosage of therapeutically effective amount of the pyrazine compound (I) varies depending on the age and condition of each individual patient to be treated, in the case of intravenous administration, a daily dose of 0.01 - 100 mg of the pyrazine compound (I) per kg weight of a human being or an animal, in the case of intramuscular administration, a daily dose of 0.1 - 100 mg of the pyrazine compound (I) per kg weight of a human being or an animal, and in case of oral administration, a daily dose of 0.5 - 100 mg of the pyrazine compound (I) per kg weight of a human being or an animal is generally given for the prevention and/or treatment of the aforesaid diseases.

20

25

The following preparations and examples are given for the purpose of illustrating the present invention in more detail.

5 The abbreviations, symbols and terms used in the preparations and examples have the following meanings.

	AcOH	acetic acid
	CHCl ₃	chloroform
	CH ₂ Cl ₂	dichloromethane
10	DME	1,2-dimethoxyethane
	DMF	N,N-dimethylformamide
	DMSO	dimethyl sulfoxide
	EtOAc	ethyl acetate
	EtOH	ethanol
15	IPA	isopropyl alcohol
	IPE	isopropyl ether
	MeOH	methanol
	MeCN	acetonitrile
	NMP	N-methylpyrrolidone
20	THF	tetrahydrofuran
	HCl	hydrochloric acid
	NEt ₃	triethylamine
	t-BuOK	potassium tert-butoxide
	K ₂ CO ₃	potassium carbonate
25	MgSO ₄	magnesium sulfate

	NaOAc	sodium acetate
	Na ₂ CO ₃	sodium carbonate
	NaH	sodium hydride
	NaHCO ₃	sodium bicarbonate
5	NaOH	sodium hydroxide
	EtI	ethyl iodide
	MeI	methyl iodide
	<i>n</i> -PrBr	<i>n</i> -propyl bromide
	<i>i</i> -PrI	isopropyl iodide
10	CuI	cuprous iodide (copper(I) iodide)
	PdCl ₂ (PPh ₃) ₂	dichlorobis(triphenylphosphine)- palladium(II)
	Pd(OAc) ₂	palladium(II) acetate
	Pd(PPh ₃) ₄	tetrakis(triphenylphosphine)- palladium(II)
15	<i>aq.</i>	aqueous
	<i>conc.</i>	concentrated
	<i>sat.</i>	saturated

20 Preparation 1

2-Methoxybromopyridine (25 g) and *n*-butyl vinyl ether (66.6 g) were dissolved in DMF (250 ml). To the solution were added 1,3-bis(diphenylphosphino)propane (3.62 g) and Pd(OAc)₂ (896 mg) and *aq.* K₂CO₃ under nitrogen
 25 atmosphere. The reaction mixture was stirred for 2 hours

at 100-120°C. The mixture was cooled to 25°C. To the solution was added 1N aq. HCl (625 ml). The solution was stirred for 1 hour at 25-30°C. The solution was portioned to EtOAc and water. The organic layer was separated. The aqueous layer
5 was extracted with EtOAc. The combined organic solution was washed with water and brine, and dried over MgSO₄. Evaporation of solvent in vacuo gave oily residue. The residue was purified by chromatography on silica gel (EtOAc : *n*-Hexane=1 : 5, v/v) to give.

10 2-methoxy-5-acetylpyridine as a solid (12.14 g).

¹H-NMR(DMSO-d₆ δ) : 2.56 (3H, s), 3.95 (3H, s), 6.92 (1H, d, J=8.4 Hz), 8.17 (1H, dd, J=2.4, 8.4 Hz), 8.30 (1H, d, J=2.4 Hz)

MS(ESI⁺) : 152[M+H]⁺

15 Preparation 2

2-Methoxy-5-acetylpyridine (12.1 g) and *t*-butyl nitrite (9.92 g) were dissolved in THF (120 ml). The solution was cooled at 0-5°C. To the solution was added *t*-BuOK (10.8 g) at 5-25°C. The reaction mixture was stirred
20 at 25°C for 2 hours. To the mixture was added 1N HCl (105 ml). The solution was portioned to EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with 10% aq. NaOAc and brine successively, dried over
25 MgSO₄. Evaporation of solvent in vacuo gave solid residue.

The residue was pulverized with IPE (150 ml). The precipitated crystals were collected by filtration, to give (1E)-(6-methoxy-3-pyridyl)(oxo)acetaldehyde oxime as a solid (5.45 g) (anti, syn mixture (anti : syn=1:1)).

- 5 Evaporation of solvent in the filtrate gave a residue. The residue was pulverized with IPE. The precipitated crystals were collected by filtration, to give (1E)-(6-methoxy-3-pyridyl)(oxo)acetaldehyde oxime as a solid (2.5 g) (anti, syn mixture (anti : syn=1:1)).

10 anti form

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 3.95 (3H, s), 6.95 (1H, d, $J=8.4$ Hz), 8.00 (1H, s), 8.23 (1H, dd, $J=2.4, 8.4$ Hz), 8.85 (1H, d, $J=2.4$ Hz), 12.7 (1H, s).

MS(ESI $^+$) : 181[M+H] $^+$, 203[M+Na] $^+$

15 syn form

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 3.96 (3H, s), 7.00 (1H, d, $J=8.4$ Hz), 7.59 (1H, s), 8.09 (1H, dd, $J=2.4, 8.4$ Hz), 8.64 (1H, d, $J=2.4$ Hz), 11.8 (1H, s),

MS(ESI $^+$) : 181[M+H] $^+$, 203[M+Na] $^+$

20 Preparation 3

(1E)-(6-Methoxy-3-pyridyl)(oxo)acetaldehyde oxime (5.4 g) and aminomalonitrile *p*-toluenesulfonate (7.6 g) were suspended in 2-propanol (108 ml) and stirred at 25°C. To the mixture was added *p*-toluenesulfonic acid (5.71 g).

- 25 The mixture was heated at 50°C for 2 hours, then at ambient

temperature for 1 hour. The above reaction mixture was concentrated in vacuo. To the concentrated solution was added sat. aq. NaOAc. Crystals were precipitated. The suspension was stirred at 20°C for 15 hours. The crystals
5 were collected by filtration, and dried in vacuo to give 3-amino-6-(6-methoxy-3-pyridyl)-2-pyrazinecarbonitrile 4-oxide as powder (6.65 g).

¹H-NMR(DMSO-d₆, δ) : 3.90 (3H, s), 6.92 (1H, d, J=8.6 Hz), 8.06 (2H, brs), 8.23 (1H, dd, J=2.4, 8.6 Hz), 8.74 (1H, d, J=2.4 Hz), 9.21 (1H, s)

MS(ESI⁺) : 244[M+H]⁺,

IR(KBr) : 3386, 3186, 2238, 1639, 1610, 1489, 1189 cm⁻¹

Preparation 4

3-Amino-6-(6-methoxy-3-pyridyl)-
15 2-pyrazinecarbonitrile 4-oxide (6.65 g) was dissolved in DMF (133 ml). To the solution was added phosphorus oxychloride (12.6 g) at 25°C. The mixture was stirred at ambient temperature for 2 hours. To the mixture was added water (520 ml). The solution was stirred at 20-25°C for 15
20 hours. The precipitated crystals were collected by filtration and dried in vacuo, to give 3-amino-5-chloro-6-(6-methoxy-3-pyridyl)-2-pyrazinecarbonitrile as powder (4.6 g). The filtrate was extracted with EtOAc. The organic solution was washed with brine, dried over MgSO₄.
25 Evaporation of solvent in vacuo gave oily residue. The

residue was purified by chromatography on silica gel (EtOAc : *n*-Hexane=1 : 1, v/v) to give 3-amino-5-chloro-6-(6-methoxy-3-pyridyl)-2-pyrazinecarbonitrile as powder (1.0 g).

5 $^1\text{H-NMR}$ (DMSO- d_6 δ) : 3.93 (3H, s), 6.92 (1H, d, $J=8.6$ Hz), 7.88 (2H, s), 7.95 (1H, dd, $J=2.4, 8.6$ Hz), 8.43 (1H, d, $J=2.4$ Hz)

MS (ESI $^+$) : 262 [M+H] $^+$, 284 [M+Na] $^+$

IR (KBr) : 3384, 3187, 2227, 1656, 1610, 1475, 1209 cm^{-1}

10 Preparation 5

2-Methoxy-5-bromo-pyridine (615 g) was dissolved in 6N HCl (3 l). The solution was heated at 99–105°C. The mixture was refluxed and stirred for 5 hours. The above reaction mixture was cooled to 5°C. The pH of the solution
15 was adjusted to 6.5 with 10% aq. NaOH. The precipitated crystal was collected by filtration and washed with water (500 ml), and dried in vacuo, to give 5-bromo-2(1H)-pyridone (570 g) as crystal.

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 6.36 (1H, d, $J=9.8$ Hz), 7.55 (1H, dd, $J=2.8, 9.8$ Hz), 7.69 (1H, d, $J=2.4$ Hz), 11.7 (1H, s)
20

MS (ESI $^+$) : 196 and 198 [M+Na] $^+$

Preparation 6

t-BuOK (32.2 g) was added to the suspension of 5-bromo-2(1H)-pyridone (50 g) in DME (500 ml). The mixture
25 was stirred for 30 minutes. To the mixture was added K_2CO_3

(27.8 g) and 2-iodopropane (81.6 g). The reaction mixture was refluxed with stirring for 3 hours. The above mixture was cooled to 20-25°C. The precipitated salt was removed by filtration and washed with DME (100 ml). Evaporation of solvent in vacuo gave solidly residue. The residue was dissolved in CHCl_3 (150 ml). The solution was washed with 0.1N HCl and brine, and dried over MgSO_4 . Evaporation of solvent in vacuo gave solidly residue. To the residue was added *n*-hexane (150 ml) to pulverize the residue. The precipitate was collected by filtration and dried in vacuo to give 5-bromo-1-isopropyl-2(1H)-pyridone (41.2 g). $^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.29 (6H, d, $J=6.8$ Hz), 4.99 (1H, m), 6.36 (1H, d, $J=9.6$ Hz), 7.48 (1H, dd, $J=2.4, 9.6$ Hz), 7.96 (1H, d, $J=2.4$ Hz)

MS(ESI $^+$) : 216 and 218[M+H] $^+$, 238 and 240[M+Na] $^+$

Preparation 7

5-Bromo-1-isopropyl-2(1H)-pyridone (50 g) was dissolved in *n*-butyl vinyl ether (250 ml). To the solution were added 1,3-bis(diphenylphosphino)propane (6.3 g) and powdered K_2CO_3 (38.2 g) and $\text{Pd}(\text{OAc})_2$ (1.56 g) at 25°C. The mixture was heated at 90-95°C with stirring for 8 hours. The reaction mixture was cooled to 25-30°C. To the cooled mixture was added CHCl_3 (125 ml). The precipitated salt was removed by filtration and washed with CHCl_3 (125 ml). Evaporation of solvent in the filtrate in vacuo gave oily

residue. The residue was dissolved in CHCl_3 (125 ml). To the solution was added 1N HCl (125 ml). The reaction mixture was stirred at 25–30°C for 1 hour. The organic layer was separated. The aqueous layer was extracted with CHCl_3 (100 ml). The combined organic layer was washed with 10% aq. NaHCO_3 (50 ml) and dried over MgSO_4 (25 g) and silica gel (25 g). MgSO_4 and silica gel were removed by filtration and washed with CHCl_3 . Evaporation of solvent in the filtrate in vacuo gave oily residue, which was crystallized from n -hexane (500 ml). The crystal was collected by filtration and dried in vacuo at 40°C, to give

5-acetyl-1-isopropyl-2(1H)-pyridone (32.35 g).

$^1\text{H-NMR}$ (DMSO-d_6 δ) : 1.37 (6H, d, $J=6.8$ Hz), 2.47 (3H, s), 5.02 (1H, m), 6.44 (1H, d, $J=9.6$ Hz), 7.82 (1H, dd, $J=2.6$, 9.6 Hz), 8.41 (1H, d, $J=2.6$ Hz)

MS (ESI $^+$) : 180 $[\text{M}+\text{H}]^+$, 202 $[\text{M}+\text{Na}]^+$

Preparation 8

5-Acetyl-1-isopropyl-2(1H)-pyridone was dissolved in CH_2Cl_2 (300 ml). The solution was cooled to -30~-25°C.

To the cooled solution were added 4N hydrogen chloride in dioxane (55.3 ml) and t -butyl nitrite (10.4 g) at -30~-25°C. The temperature of the reaction mixture was raised to 20–25°C. The mixture was stirred at the same temperature for 3 hours. The precipitated crystal was collected by filtration, and dried in the air at ambient temperature,

to give (1E)-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)(oxo)acetaldehyde oxime (14.0 g).

¹H-NMR(DMSO-d₆ δ) : 1.35 (6H, d, J=6.8 Hz), 5.02 (1H, m),
6.47 (1H, d, J=9.6 Hz), 7.89 (1H, dd, J=2.4, 9.6 Hz), 8.00
5 (1H, s), 8.69 (1H, d, J=2.4 Hz), 12.65 (1H, brs)

MS(ESI⁺) : 209[M+H]⁺, 231[M+Na]⁺

IR(KBr) : 3129, 1660, 1617, 1529, 1018 cm⁻¹

Preparation 9

The mixture of (1E)-(1-isopropyl-6-oxo-1,6-dihydro-
10 3-pyridyl)(oxo)acetaldehyde oxime (14 g) and
aminomalonitrile *p*-toluenesulfonate (17 g) and IPA (210 ml)
was heated at 75-80°C and stirred for 2 hours at the same
temperature. The reaction mixture was cooled to 0-5°C and
stirred for 2 hours. The precipitate was collected by
15 filtration, and dried in vacuo, to give 3-amino-
6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
2-pyrazinecarbonitrile 4-oxide (9.2 g).

¹H-NMR(DMSO-d₆ δ) : 1.36 (6H, d, J=6.8 Hz), 5.09 (1H, m),
6.48 (1H, d, J=9.6 Hz), 7.92-7.99 (3H, m), 8.28 (1H, d, J=2.6
20 Hz), 9.25 (1H, s)

MS(ESI⁺) : 293[M+Na]⁺

IR(KBr) : 3122, 2200, 1656, 1598, 1531, 1174 cm⁻¹

Preparation 10

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-
25 3-pyridyl)-2-pyrazinecarbonitrile 4-oxide (9 g) was

dissolved in 25% hydrogen bromide solution of AcOH (90 ml) at 20-25°C. The reaction mixture was stirred for 2 hours at ambient temperature. To the reaction mixture was added dioxane (180 ml). The suspension was stirred for 2 hours at ambient temperature. The precipitate was collected by filtration and washed with dioxane, and dried in the air at ambient temperature. The above powder was suspended in water (90 ml). The pH of the suspension was adjusted to 8-8.5 with 1N NaOH (70 ml). The suspension was stirred at ambient temperature. The precipitate was collected by filtration and washed with water, and dried in vacuo at 50°C, to give 3-amino- 6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide 4-oxide (8.80 g).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.39 (6H, d, $J=6.8$ Hz), 5.10 (1H, m), 6.46 (1H, d, $J=9.4$ Hz), 7.88 (2H, s), 7.89 (1H, s), 8.32 (1H, dd, $J=2.4, 9.4$ Hz), 8.41 (1H, d, $J=2.4$ Hz), 8.51 (1H, s), 9.15 (1H, s)

MS(ESI $^+$) : 312[M+Na] $^+$

IR(KBr) : 3440, 1660, 1596, 1554, 1186 cm^{-1}

20 Preparation 11

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide 4-oxide (8 g) was dissolved in DMF (80 ml). The solution was cooled to -30°C. To the cooled solution was added phosphoryl chloride (12.7 g) dropwise at -30~-40°C. After addition of phosphoryl

chloride, the temperature of the reaction mixture was raised to -10~-5°C. The mixture was stirred at -10~-5°C for 1 hour. To the reaction mixture was added water (400 ml). The suspension was stirred at 30-35°C for 15 hours. The pH of the suspension was adjusted to 4.5. The suspension was cooled to 0-5°C and stirred at the same temperature for 2 hours. The precipitate was collected by filtration and washed with water, and dried in vacuo at 40-50°C, to give 3-amino-5-chloro-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (7.1 g).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.34 (6H, d, $J=7.0$ Hz), 5.09 (1H, m), 6.44 (1H, d, $J=9.4$ Hz), 7.74 (1H, s), 7.85 (1H, dd, $J=2.4$, 9.4 Hz), 7.85 (2H, s), 8.13 (1H, d, $J=2.4$ Hz), 8.13 (1H, s)

MS(ESI $^+$) : 330 and 332[M+Na] $^+$

IR(KBr) : 3284, 1673, 1604, 1461, 1187 cm^{-1}

Preparation 12

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide 4-oxide (29.1 g) was dissolved in DMF (290 ml). The solution was cooled to -30°C. To the cooled solution was added phosphoryl chloride (46.3 g) dropwise at -30~-40°C. After addition of phosphoryl chloride, the temperature of the reaction mixture was raised to 40-45°C. The mixture was stirred at 40-45°C for 1 hour. To the reaction mixture was added water (1160 ml).

The suspension was stirred at 30-35°C for 15 hours. The pH of the suspension was adjusted to 7 with 12% aq. NaOH (400 ml). The suspension was cooled to 0-5°C and stirred at the same temperature for 2 hours. The precipitate was collected
5 by filtration and washed with water, and dried in vacuo at 40-50°C, to give 3-amino-5-chloro-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile (17.2 g).
¹H-NMR(DMSO-d₆ δ) : 1.34 (6H, d, J=7.0 Hz), 5.09 (1H, m), 6.44 (1H, d, J=9.4 Hz), 7.74 (1H, s), 7.85 (1H, dd, J=2.4, 9.4 Hz), 7.85 (2H, s), 8.13 (1H, d, J=2.4 Hz), 8.13 (1H, s)
10
MS(ESI⁺) : 330[M+Na]⁺
IR(KBr) : 3291, 1662, 1600, 1465, 1182 cm⁻¹

Preparation 13

15 To a solution of 1-(diphenylmethyl)-3-azetidinol hydrochloride (5.0 g) in DMF (25 ml), was added sodium hydride under ice-bath cooling. After 10 minute stirring at the same temperature, the mixture was allowed to warm to 25°C and then stirred for 15 hours. EtOAc (500 ml) and
20 water (200 ml) were poured into the mixture. The organic layer was separated, washed with water and brine, and dried over MgSO₄. The solvent was removed under reduced pressure. The residue was purified by column chromatography (silica gel; 200 ml, toluene : EtOAc=15 : 1 - 8 : 1) to give
25 1-(diphenylmethyl)-3-methoxyazetidine (3.41 g).

$^1\text{H-NMR}$ (DMSO- d_6 , δ) : 2.7-2.9 (2H, m), 3.12 (3H, s), 3.3-3.5 (2H, m), 3.99 (1H, m), 4.40 (1H, s), 7.1-7.4 (6H, m), 7.3-7.5 (4H, m)
MS (ESI $^+$) : 254[M+H] $^+$

5 Preparation 14

To a solution of 1-(diphenylmethyl)-3-methoxyazetidine (3.4 g) in MeOH (35 ml), was added 20% palladium hydroxide on carbon (0.7 g). And then the mixture was stirred under hydrogen atmosphere for 2.5 hours. 1N HCl (20
10 ml) was added to the mixture and the catalyst was removed by filtration and washed with 1N HCl. The solvent was removed under reduced pressure. Water and EtOAc were poured into the residue, and the aqueous layer was separated, washed with EtOAc. The solvent was removed under reduced
15 pressure and the residue was azeotroped with EtOH and dried in vacuo. *n*-Hexane was poured into the residue and a crystal was isolated by filtration, washed with *n*-hexane, and dried in vacuo to give 3-methoxyazetidine hydrochloride (1.58 g).

$^1\text{H-NMR}$ (DMSO- d_6 , δ) : 3.21 (3H, s), 3.6-3.9 (2H, m), 4.0-4.4
20 (3H, m)
MS (ESI $^+$) : 88[M+H] $^+$ (free form)

Preparation 15

The mixture of 5-bromo-2(1H)-pyridone (200 g) and MeI (324 g) and K_2CO_3 (318 g) in DME (2 l) was heated at 80°C
25 with stirring for 2 hours. The above mixture was cooled to

room temperature. The precipitated salt was removed by filtration and washed with DME. Evaporation of solvent in the filtrate in vacuo gave oily residue. The residue was portioned to EtOAc and water. The organic layer was separated. Aqueous layer was extracted with EtOAc twice. The combined organic solution was dried over MgSO_4 . Evaporation of solvent in vacuo gave crystal residue. The residue was pulverized with IPE and *n*-hexane (1 : 3, 1000 ml). The precipitate was collected by filtration and dried in vacuo to give 5-bromo-1-methyl-2(1*H*)-pyridone as white powder (182.5 g).

$^1\text{H-NMR}$ (DMSO-d_6 , δ) : 3.40 (3H, s), 6.36 (1H, d, $J=9.6$ Hz), 7.51 (1H, dd, $J=2.8, 9.6$ Hz), 8.03 (1H, d, $J=2.8$ Hz)
 $\text{MS}(\text{ESI}^+)$: 210 and 212 [$\text{M}+\text{Na}$] $^+$

15 Preparation 16

5-Bromo-1-methyl-2(1*H*)-pyridone (150 g) was dissolved in DMF (1500 ml). To the solution were added 1,3-bis(diphenylphosphino)propane (21.7 g), *n*-butyl vinyl ether (400 g), and 3*M* aq. potassium carbonate (262.5 ml) and $\text{Pd}(\text{OAc})_2$ (10.2 g). The mixture was heated at 80°C and stirred for 3 hours at the same temperature. The reaction mixture was cooled to 25-30°C and poured to 1*N* HCl (1485 ml). The mixture was stirred for 2 hours at 30-40°C. The solution was extracted with EtOAc (1500 ml, three times). The aqueous layer was extracted with CH_2Cl_2 (1000 ml, three

times). The collected organic solution was dried over MgSO_4 . Evaporation of solvent gave solidly residue, which was pulverized with IPA (150 ml) and IPE (1500 ml). The suspension was stood in the refrigerator overnight. The precipitate was collected by filtration, dried in vacuo, to give 5-acetyl-1-methyl-2(1H)-pyridone as white powder (128 g).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 2.41 (3H, s), 3.52 (3H, s), 6.42 (1H, d, $J=9.6$ Hz), 7.84 (1H, dd, $J=2.4, 9.6$ Hz), 8.66 (1H, d, $J=2.4$ Hz)

MS(ESI $^+$) : 152[M+H] $^+$, 174[M+Na] $^+$

Preparation 17

(1E)-(1-Methyl-6-oxo-1,6-dihydro-3-pyridyl)(oxo)acetaldehyde oxime

The title compound was obtained in a similar manner to that of Preparation 8.

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 3.57 (3H, s), 6.47 (1H, d, $J=9.6$ Hz), 7.93 (1H, dd, $J=2.4, 9.6$ Hz), 8.03 (1H, s), 8.76 (1H, d, $J=2.4$ Hz), 12.62 (1H, s)

MS(ESI $^+$) : 203[M+Na] $^+$

Preparation 18

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile 4-oxide

The title compound was obtained in a similar manner to that of Preparation 9.

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 3.50 (3H, s), 6.47 (1H, d, $J=9.6$ Hz),
7.96 (2H, s), 7.96-8.02 (1H, m), 8.43 (1H, d, $J=2.4$ Hz),
9.04 (1H, s)

MS (ESI $^+$) : 244 [M+Na] $^+$

5 Preparation 19

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-
3-pyridyl)-2-pyrazinecarbonitrile 4-oxide (97 g) was added
to 25% hydrogen bromide solution of AcOH (700 ml) at 25-30°C.
The mixture was stirred for 2 hours at ambient temperature.

10 To the mixture was added 12% aq. NaOH (2100 ml) and water
(1000 ml). The mixture was stirred overnight at the
refrigerator. The resultant precipitated crystals were
collected by filtration, and washed with water, and dried
in vacuo, to give 3-amino-6-(1-methyl-6-oxo-1,6-dihydro-

15 3-pyridyl)-2-pyrazinecarboxamide 4-oxide as powder (52 g).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 3.52 (3H, s), 6.45 (1H, d, $J=9.6$ Hz),
7.82 (2H, s), 7.92 (1H, s), 8.26 (1H, dd, $J=2.6, 9.6$ Hz),
8.54 (1H, s), 8.72 (1H, d, $J=2.6$ Hz), 8.97 (1H, s).

MS (ESI $^+$) : 262 [M+H] $^+$, 284 [M+Na] $^+$

20 Preparation 20

3-Amino-5-chloro-6-(1-methyl-6-oxo-1,6-dihydro-
3-pyridyl)-2-pyrazinecarbonitrile

The title compound was obtained in a similar manner
to that of Preparation 12.

25 $^1\text{H-NMR}$ (DMSO- d_6 δ) : 3.25 (3H, s), 6.45 (1H, d, $J=9.4$ Hz),

7.70 (1H, dd, J=2.6, 9.4 Hz), 7.83 (2H, s), 8.06 (1H, d, J=2.6 Hz)

MS(ESI⁺) : 262 and 263[M+H]⁺, 284 and 286[M+Na]⁺

Preparation 21

5 To a suspension of 3-amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide 4-oxide (1.0 g) in DMF was added phosphoric trichloride (1.07 ml) at -40°C for 20 minutes. This reaction mixture was warmed to -10°C and stirred for 1 hour. To this solution was added
10 water (40 ml) and stirred at 40°C for 14 hours. The pH of the resulting suspension was adjusted to 4.5 with 30% The pH of the aqueous mixture was adjusted to 6-7 with 12% aq. NaOH. The precipitate was collected by filtration and washed with water to give 3-amino-5-chloro-6-(1-methyl-
15 6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (263 mg) as a yellow powder.

MS(ESI⁺) : 280[M+H]⁺

Example 1

3-Amino-5-chloro-6-(6-methoxy-3-pyridyl)-
20 2-pyrazinecarbonitrile (1.35 g) was dissolved in dioxane (135 ml). To the solution were added phenylboronic acid (1.89 g) and Pd(PPh₃)₄ (179 mg) and Na₂CO₃ (2.19 g) in water (27 ml) at 25°C. The reaction mixture was heated at 80°C for 2 hours, then at ambient temperature for 3 hours. The
25 above mixture was portioned to EtOAc and water. The organic

layer was separated and washed with aq. Na_2CO_3 and brine, and dried over MgSO_4 . Evaporation of solvent in vacuo gave oily residue, which was purified by chromatography on silica gel (EtOAc : *n*-Hexane=1 : 1, v/v) to give

5 3-amino-6-(6-methoxy-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile as yellow crystal which was crystallized from EtOAc (1.15 g).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 3.81 (3H, s), 6.73 (1H, d, $J=8.6$ Hz),
7.35 (5H, s), 7.51 (2H, s), 7.54 (1H, dd, $J=2.4, 8.6$ Hz),
10 7.99 (1H, d, $J=2.4$ Hz)

MS(ESI $^+$) : 304[M+H] $^+$, 326[M+Na] $^+$

IR(KBr) : 3357, 3183, 2238, 1648, 1598, 1544, 1195 cm^{-1}

m.p. : 201-205°C (IPE)

Example 2

15 3-Amino-6-(6-methoxy-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (500 mg) was dissolved in dioxane (10 ml) and conc. HCl (5 ml). The solution was stirred at 80°C for 5 hours. The reaction mixture was cooled to 25-30°C and concentrated in vacuo to give a residue. To the residue
20 was added water and 1N NaOH to adjust the pH of the aqueous mixture to 6-7. The precipitated crystals were collected by filtration dried in vacuo to give 3-amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (390 mg).

25 $^1\text{H-NMR}$ (DMSO- d_6 δ) : 6.16 (1H, d, $J=9.4$ Hz), 7.26-7.70 (10H,

m), 8.23 (1H, s), 11.66 (1H, s)

MS(ESI⁺) : 330[M+Na]⁺

MS(ESI⁻) : 306[M-H]⁻

IR(KBr) : 3309, 1656, 1610, 1544, 1201 cm⁻¹

5 m.p. : 215-220°C (H₂O)

Example 3

3-Amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-
2-pyrazinecarboxamide (61.4 mg) was dissolved in DMF (1 ml).
To the solution were added 1M MeI solution in DMF (0.22 ml)
10 and 0.1M t-BuOK solution in DMF (2.2 ml). The mixture was
stirred at 20-30°C for 2 hours. The reaction mixture was
portioned EtOAc and water. The organic layer was separated.
The aqueous layer was extracted with EtOAc. The combined
organic solution was washed with brine and dried over MgSO₄.
15 Evaporation of solvent gave oily residue. The above residue
was purified by chromatography on silica gel (EtOAc only
- EtOAc : MeOH=93 : 7, v/v) to give 3-amino-
6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-
2-pyrazinecarboxamide, which was crystallized from EtOAc
20 (20 mg).

¹H-NMR(DMSO-d₆ δ) : 3.45 (3H, s), 6.12 (1H, d, J=9.4 Hz),
6.97 (1H, dd, J=2.4, 9.4 Hz), 7.41-7.62 (8H, m), 8.14 (1H,
d, J=2.4 Hz), 8.29 (1H, s)

MS(ESI⁺) : 344[M+Na]⁺

25 IR(KBr) : 3353, 1664, 1599, 1531, 1438 cm⁻¹

m.p. : >250°C (EtOAc)

Example 4

3-Amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-
5-phenyl-2-pyrazinecarboxamide

5 The title compound was obtained in a similar manner
to that of Example 3.

¹H-NMR(DMSO-d₆ δ) : 1.12 (3H, t, J=7.0 Hz), 3.84 (2H, q,
J=7.0 Hz), 6.18 (1H, d, J=9.4 Hz), 7.21 (1H, dd, J=2.4, 9.4
Hz), 7.40-7.72 (8H, m), 7.89 (1H, d, J=2.4 Hz), 8.27 (1H,

10 s)

MS(ESI⁺) : 336[M+H]⁺, 358[M+Na]⁺

IR(KBr) : 3154, 1679, 1597, 1535, 1444 cm⁻¹

m.p. : >250°C (EtOAc)

Example 5

15 3-Amino-6-(6-oxo-1-propyl-1,6-dihydro-3-pyridyl)-
5-phenyl-2-pyrazinecarboxamide

The title compound was obtained in a similar manner
to that of Preparation 3.

¹H-NMR(DMSO-d₆ δ) : 0.77 (3H, t, J=7.4 Hz), 1.52 (2H, m),
20 3.76 (2H, t, J=7.2 Hz), 6.20 (1H, d, J=9.4 Hz), 7.34-7.47
(8H, m), 7.66-7.72 (2H, m), 8.19 (1H, s)

MS(ESI⁺) : 350[M+H]⁺, 372[M+Na]⁺

IR(KBr) : 3421, 1650, 1571, 1515, 1417cm⁻¹

m.p. : >250°C (EtOAc)

25 Example 6

3-Amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-
2-pyrazinecarboxamide (92.1 mg) was dissolved in DMF (1 ml).
To the solution were added 1M *i*-PrI solution in DMF (0.33
ml) and 0.1M *t*-BuOK solution in DMF (3.3 ml). The mixture
5 was stirred at 20-30°C for 2 hours. The reaction mixture
was portioned EtOAc and water. The organic layer was
separated. The aqueous layer was extracted with EtOAc. The
combined organic solution was washed with brine and dried
over MgSO₄. Evaporation of solvent gave oily residue. The
10 above residue was purified by chromatography on silica gel
(EtOAc only - EtOAc : MeOH=96 : 4, v/v) to give
3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
5-phenyl-2-pyrazinecarboxamide (18 mg) and 3-amino-
6-(6-isopropoxy-3-pyridyl)-5-phenyl-2-pyrazine-
15 carboxamide (42 mg).
3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
5-phenyl-2-pyrazinecarboxamide
¹H-NMR(DMSO-d₆ δ) : 0.97 (6H, d, J=6.8 Hz), 4.90 (1H, m),
6.20 (1H, d, J=9.4 Hz), 7.34-7.47 (8H, m), 7.66-7.72 (2H,
20 m), 8.19 (1H, s)
MS(ESI⁺) : 350 [M+H]⁺, 372 [M+Na]⁺
IR(KBr) : 3417, 1664, 1591, 1533, 1450 cm⁻¹
m.p. : 240-245°C (EtOAc)
3-Amino-6-(6-isopropoxy-3-pyridyl)-5-phenyl-2-pyrazine-
25 carboxamide

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.26 (6H, d, $J=6.8$ Hz), 5.20 (1H, m),
6.60 (1H, d, $J=8.6$ Hz), 7.42 (5H, s), 7.60-7.67 (3H, m),
8.17 (2H, s)

MS (ESI $^+$) : 350 [M+H] $^+$, 372 [M+Na] $^+$

5 IR (KBr) : 3471, 1683, 1656, 1600, 1488 cm^{-1}

Example 7

3-Amino-6-(6-methoxy-3-pyridyl)-5-phenyl-
2-pyrazinecarbonitrile (800 mg) was dissolved in dioxane
and conc. HCl. The solution was stirred at 80°C for 15 hours.
10 Dioxane was evaporated out. The reaction mixture was cooled
to room temperature and concentrated in vacuo to give
residue. To the residue was added 1N NaOH to adjust the pH
of the aqueous mixture to 6-7. The crystals were collected
by filtration, and dried in vacuo to give 3-amino-6-(6-oxo-
15 1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic
acid as powder (600 mg).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 6.18 (1H, d, $J=9.4$ Hz), 7.25-7.65 (9H,
m), 11.8 (2H, brs)

MS (ESI $^-$) : 307 [M-H] $^-$

20 Example 8

3-Amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-
2-pyrazinecarboxylic acid (154 mg) was dissolved in DMF (5
ml). To the solution were added EtI (86.1 mg) and *t*-BuOK
(61.9 mg). The mixture was stirred at 20-30°C for 2 hours.
25 The reaction mixture was portioned EtOAc and water. The

- organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over MgSO_4 . Evaporation of solvent gave oily residue. The above residue was purified
- 5 by chromatography on silica gel (EtOAc only - EtOAc : MeOH=95 : 5, v/v) to give ethyl 3-amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate (84 mg) and ethyl 3-amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate (28 mg).
- 10 Ethyl 3-amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate
- $^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.34 (3H, t, $J=7.0$ Hz), 4.37 (2H, q, $J=7.0$ Hz), 6.23 (1H, d, $J=9.4$ Hz), 7.19 (1H, d, $J=2.4$ Hz), 7.25 (1H, dd, $J=2.4, 9.4$ Hz), 7.40-7.52 (5H, m)
- 15 MS(ESI^+) : 359[M+Na] $^+$
- IR(KBr) : 3400, 1697, 1614, 1434, 1130 cm^{-1}
- m.p. : 230-238°C (EtOAc)
- Ethyl 3-amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate
- 20 $^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.00 (3H, t, $J=7.0$ Hz), 1.34 (3H, t, $J=7.0$ Hz), 3.76 (2H, q, $J=7.0$ Hz), 4.37 (2H, q, $J=7.0$ Hz), 6.32 (1H, d, $J=9.4$ Hz), 7.32 (1H, dd, $J=2.6, 9.4$ Hz), 7.36-7.5 (8H, m)
- MS(ESI^+) : 365[M+H] $^+$, 387[M+Na] $^+$
- 25 IR(KBr) : 3400, 1662, 1600, 1440, 1122 cm^{-1}

m.p. : 175-179°C (EtOAc)

Example 9

3-Amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-
2-pyrazinecarboxylic acid (283 mg) was dissolved in DMF (10
5 ml). To the solution were added *i*-PrI (172 mg) and *t*-BuOK
(114 mg). The mixture was stirred at 20-30°C for 2 hours.
The reaction mixture was portioned EtOAc and water. The
organic layer was separated. The aqueous layer was
extracted with EtOAc. The combined organic solution was
10 washed with brine and dried over MgSO₄. Evaporation of
solvent gave oily residue. The above residue was purified
by chromatography on silica gel (EtOAc only - EtOAc :
MeOH=96 : 4, v/v) to give isopropyl 3-amino-6-(6-oxo-
1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate
15 as yellow crystal (64mg).

¹H-NMR(DMSO-d₆ δ) : 1.35 (6H, d, J=6.2 Hz), 5.20 (1H, m),
6.23 (1H, d, J=9.4Hz), 7.19 (1H, d, J=2.2 Hz), 7.22 (1H,
dd, J=2.2, 9.4 Hz), 7.40 (5H, m), 11.6 (1H, s)

MS(ESI⁺) : 351[M+H]⁺, 373[M+Na]⁺

20 IR(KBr) : 3425, 1666, 1612, 1434, 1101 cm⁻¹

m.p. : 250-256°C (EtOAc)

Example 10

3-Amino-6-(6-methoxy-3-pyridyl)-5-phenyl-
2-pyrazinecarbonitrile (370 mg) was dissolved in
25 1,2-dichloroethane (37 ml). To the solution was added 1M

boron tribromide solution in CH_2Cl_2 (12.2 ml). The mixture was stirred at 80°C for 24 hours. The mixture was cooled to $20\text{--}25^\circ\text{C}$, and portioned to EtOAc and water. The organic layer was separated. The aqueous layer was extracted with
5 EtOAc. The combined organic layer was washed with brine, and dried over MgSO_4 . Evaporation of solvent in vacuo gave reddish solid residue. The residue was pulverized with water, to give 3-amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile as powder (254 mg).

10 $^1\text{H-NMR}$ (DMSO-d_6 , δ) : 6.21 (1H, d, $J=9.4$ Hz), 7.20-7.98 (7H, m), 11.6 (1H, s)

MS(ESI^+) : 312 [$\text{M}+\text{Na}$] $^+$

IR(KBr) : 3326, 2221, 1656, 1610, 1544, 1201 cm^{-1}

m.p. : $243\text{--}248^\circ\text{C}$ (H_2O)

15 Example 11

3-Amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (58 mg) was dissolved in DMF (1 ml). To the solution were added 1M MeI solution in DMF (0.22 ml) and 0.1M *t*-BuOK solution in DMF (2.2 ml). The mixture was
20 stirred at $20\text{--}30^\circ\text{C}$ for 2 hours. The reaction mixture was portioned EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over MgSO_4 . Evaporation of solvent gave oily residue. The above residue
25 was purified by chromatography on silica gel (EtOAc only)

- EtOAc : MeOH=93 : 7, v/v) to give 3-amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazine-carbonitrile, which was crystallized from EtOAc (18 mg).
 $^1\text{H-NMR}$ (DMSO- d_6 δ) : 3.40 (3H, s), 6.17 (1H, d, $J=9.4$ Hz),
5 6.97 (1H, dd, $J=2.6$, 9.4 Hz), 7.40-7.50 (7H, m), 7.81 (1H, d, $J=2.6$ Hz)
MS (ESI $^+$) : 304[M+H] $^+$, 326[M+Na] $^+$
IR (KBr) : 3386, 2221, 1670, 1590, 1542, 1205 cm^{-1}
m.p. : $>250^\circ\text{C}$ (EtOAc)

10 Example 12

3-Amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile

The title compound was obtained in a similar manner to that of Example 11.

15 $^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.03 (3H, t, $J=7.0$ Hz), 3.79 (2H, q, $J=7.0$ Hz), 6.25 (1H, d, $J=9.4$ Hz), 7.19 (1H, dd, $J=2.6$, 9.4 Hz), 7.44-7.47 (7H, m), 7.58 (1H, d, $J=2.6$ Hz)
MS (ESI $^+$) : 318[M+H] $^+$, 340[M+Na] $^+$
IR (KBr) : 3180, 2221, 1657, 1587, 1535, 1203 cm^{-1}
20 m.p. : $193-199^\circ\text{C}$ (IPE)

Example 13

3-Amino-6-(6-oxo-1-propyl-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (17 mg)

The title compound was obtained in a similar manner to that of Example 11.

$^1\text{H-NMR}$ (DMSO- d_6 , δ) : 0.71 (3H, t, $J=7.4$ Hz), 1.44 (2H, m),
3.73 (2H, t, $J=7.2$ Hz), 6.26 (1H, d, $J=9.4$ Hz), 7.20 (1H,
dd, $J=2.6, 9.4$ Hz), 7.38-7.47 (7H, m), 7.54 (1H, d, $J=2.6$
Hz)

5 MS(ESI $^+$) : 332[M+H] $^+$, 354[M+Na] $^+$

IR(KBr) : 3311, 2220, 1658, 1536, 1463, 1201 cm^{-1}

m.p. : 180-183°C (IPE)

Example 14

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
10 5-phenyl-2-pyrazinecarbonitrile

The title compound was obtained in a similar manner
to that of Example 11.

$^1\text{H-NMR}$ (DMSO- d_6 , δ) : 0.94 (6H, d, $J=6.8$ Hz), 4.85-4.92 (1H,
m), 6.35 (1H, d, $J=9.4$ Hz), 7.28 (1H, d, $J=2.4$ Hz), 7.38-7.49
15 (8H, m)

MS(ESI $^+$) : 332[M+H] $^+$, 354[M+Na] $^+$

IR(KBr) : 3426, 2225, 1664, 1621, 1552, 1106 cm^{-1}

m.p. : 204.5°C (95% aq. 2-propanol)

Example 15

20 3-Amino-6-(6-methoxy-3-pyridyl)-5-phenyl-
2-pyrazinecarbonitrile (100 mg) was dissolved in 30%
hydrogen bromide solution in AcOH (1 ml). The solution was
stirred at 25-30°C for 3 hours. To the solution was added
water. The pH of the aqueous mixture was adjusted to 6-7
25 with 12% aq. NaOH. The crystals were precipitated. The

suspension was stirred at 25-30°C for 3 hours, and stood for 10 hours in refrigerator. The crystals was collected by filtration and dried in vacuo, to give 3-amino-6-(6-methoxy-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide

5 (92.5 mg).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 3.82 (3H, s), 6.69 (1H, d, $J=6.6$ Hz), 7.39 (5H, s), 7.64-7.70 (3H, m), 8.17 (2H, s)

MS(ESI $^+$) : 322[M+H] $^+$, 344[M+Na] $^+$

IR(KBr) : 3411, 3276, 1689, 1598, 1496, 1286 cm^{-1}

10 m.p. : 208-212°C (H_2O)

The following 24 compounds were obtained in a similar manner to that of Example 1.

Example 16

3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

15 5-phenyl-2-pyrazinecarboxamide

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.97 (6H, d, $J=6.8$ Hz), 4.90 (1H, m), 6.32 (1H, d, $J=9.4$ Hz), 7.34-7.46 (6H, m), 7.66-7.72 (4H, m), 8.19 (1H, s)

MS(ESI $^+$) : 350[M+H] $^+$, 372[M+Na] $^+$

20 IR(KBr) : 3417, 1664, 1590, 1533, 1450 cm^{-1}

mp : 245°C (IPA- H_2O)

Example 17

3-Amino-5-(2-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

25 $^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.93 (6H, d, $J=6.8$ Hz), 4.89 (1H, m),

6.35 (1H, d, J=9.4 Hz), 7.22-7.81 (9H, m), 8.22 (1H, s)

MS(ESI⁺) : 368[M+H]⁺, 390[M+Na]⁺

IR(KBr) : 3367, 1664, 1600, 1446, 1205 cm⁻¹

mp : 251.7°C (IPA-H₂O)

5 Example 18

3-Amino-5-(3-fluorophenyl)-6-(1-isopropyl-6-oxo-
1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 1.01 (6H, d, J=6.8 Hz), 4.93 (1H, m),

6.35 (1H, d, J=9.4 Hz), 7.21-7.71 (9H, m), 8.22 (1H, s)

10 MS(ESI⁺) : 368[M+H]⁺, 390[M+Na]⁺

IR(KBr) : 3394, 1658, 1590, 1533, 1452 cm⁻¹

mp : 258.8°C (IPA-H₂O)

Example 19

3-Amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-

15 1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 0.97 (6H, d, J=6.8 Hz), 4.90 (1H, m),

6.32 (1H, d, J=9.4 Hz), 7.34-7.46 (6H, m), 7.66-7.72 (3H,

m), 8.19 (1H, s)

MS(ESI⁺) : 390[M+Na]⁺

20 IR(KBr) : 3293, 1660, 1583, 1450, 1153 cm⁻¹

mp : 235.6°C (IPA-H₂O)

Example 20

3-Amino-5-(2-chlorophenyl)-6-(1-isopropyl-6-oxo-

1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

25 ¹H-NMR(DMSO-d₆ δ) : 0.90 (6H, m), 4.87 (1H, m), 6.34 (1H,

d, J=9.4 Hz), 7.16 (1H, d, J=2.4 Hz), 7.48-7.68 (6H, m), 7.73

(1H, s), 7.82 (1H, dd, J=2.4, 9.4 Hz), 8.24 (1H, s)

MS(ESI⁺) : 384[M+H]⁺, 406[M+Na]⁺

IR(KBr) : 3367, 1666, 1604, 1454, 1157 cm⁻¹

5 mp: 254.5°C (IPA-H₂O)

Example 21

3-Amino-5-(3-chlorophenyl)-6-(1-isopropyl-6-oxo-

1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 1.01 (6H, d, J=6.8 Hz), 4.93 (1H, m),

10 6.35 (1H, d, J=9.4 Hz), 7.35-7.46 (5H, m), 7.49 (2H, s),

7.57-7.72 (3H, m), 8.21 (1H, s)

MS(ESI⁺) : 384[M+H]⁺, 406[M+Na]⁺

IR(KBr) : 3396, 1658, 1589, 1452, 1250 cm⁻¹

mp: 232.6°C (IPA-H₂O)

15 Example 22

3-Amino-5-(4-chlorophenyl)-6-(1-isopropyl-6-oxo-

1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 1.02 (6H, d, J=6.8 Hz), 4.94 (1H, m),

6.34 (1H, d, J=9.4 Hz), 7.40 (1H, d, J=2.4Hz), 7.49 (6H,

20 s), 7.65 (1H, dd, J=2.4, 9.4 Hz), 7.70 (1H, s), 8.21 (1H,

s)

MS(ESI⁺) : 406[M+Na]⁺

IR(KBr) : 3278, 1664, 1587, 1450, 1093 cm⁻¹

mp: 246.2°C (IPA-H₂O)

25 Example 23

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(2-methoxyphenyl)-2-pyrazinecarboxamide

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.89-1.05 (6H, m), 3.48 (3H, s), 4.88

(1H, m), 6.32 (1H, d, $J=9.4$ Hz), 6.99-7.13 (2H, m), 7.22

5 (1H, d, $J=2.4$ Hz), 7.37-7.65 (2H, m), 7.59 (2H, brs), 7.66

(1H, s), 7.75 (1H, dd, $J=2.4, 9.4$ Hz), 8.16 (1H, s)

MS(ESI $^+$) : 380[M+H] $^+$, 402[M+Na] $^+$

IR(KBr) : 3259, 1662, 1596, 1452, 1259 cm^{-1}

mp : 263.1 $^{\circ}\text{C}$ (IPA- H_2O)

10 Example 24

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(3-methoxyphenyl)-2-pyrazinecarboxamide

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.01 (6H, d, $J=6.8$ Hz), 3.71 (3H, s),

4.90 (1H, m), 6.33 (1H, d, $J=9.4$ Hz), 6.94-7.02 (3H, m),

15 7.30-7.39 (2H, m), 7.65-7.71 (3H, m), 8.19 (1H, s)

MS(ESI $^+$) : 380[M+H] $^+$, 402[M+Na] $^+$

IR(KBr) : 3442, 1660, 1581, 1444, 1268 cm^{-1}

IR(KBr) : 3442, 1660, 1581, 1444, 1268 cm^{-1}

mp : 192.3 $^{\circ}\text{C}$ (IPA- H_2O)

20 Example 25

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(4-methoxyphenyl)-2-pyrazinecarboxamide

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.05 (6H, d, $J=6.8$ Hz), 3.77 (3H, s),

4.94 (1H, m), 6.32 (1H, d, $J=9.4$ Hz), 6.97 (2H, d, $J=8.8$

25 Hz), 7.42 (2H, d, $J=8.8$ Hz), 7.45-7.64 (5H, m), 8.15 (1H,

s)

MS(ESI⁺) : 380[M+H]⁺, 402[M+Na]⁺

IR(KBr) : 3266, 1664, 1600, 1448, 1255 cm⁻¹

mp : 243.9°C (IPA-H₂O)

5 Example 26

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-[2-(trifluoromethoxy)phenyl]-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 0.90 (6H, m), 4.88 (1H, m), 6.34 (1H, d, J=9.4 Hz), 7.20 (1H, d, J=2.4 Hz), 7.34-7.39 (1H, m),

10 7.54-7.78 (7H, m), 8.24 (1H, s)

MS(ESI⁺) : 434[M+H]⁺, 456[M+Na]⁺

IR(KBr) : 3386, 1662, 1596, 1257, 1162 cm⁻¹

mp : 206.5°C (IPA-H₂O)

Example 27

15 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-[3-(trifluoromethoxy)phenyl]-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 0.98 (6H, d, J=6.8 Hz), 4.88 (1H, m), 6.35 (1H, d, J=9.4 Hz), 7.37-7.81 (9H, m), 8.22 (1H, s)

MS(ESI⁺) : 434[M+H]⁺, 456[M+Na]⁺

20 IR(KBr) : 3403, 1660, 1592, 1452, 1263 cm⁻¹

mp : 265.5°C (IPA-H₂O)

Example 28

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-[4-(trifluoromethoxy)phenyl]-2-pyrazinecarboxamide

25 ¹H-NMR(DMSO-d₆ δ) : 0.98 (6H, d, J=6.8 Hz), 4.91 (1H, m),

6.37 (1H, d, J=9.4 Hz), 7.30 (1H, d, J=2.4Hz), 7.42 (2H, d, J=8.2Hz), 7.58 (2H, d, J=8.2Hz), 7.70 (3H, m), 7.78 (1H, dd, J=2.4, 9.4Hz), 8.21 (1H, s)

MS(ESI⁺) : 434[M+H]⁺, 456[M+Na]⁺

5 IR(KBr) : 3403, 1660, 1592, 1452, 1263 cm⁻¹

mp : 264.0°C (IPA-H₂O)

Example 29

3-Amino-5-(3,4-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

10 ¹H-NMR(DMSO-d₆ δ) : 1.05 (6H, d, J=6.8 Hz), 4.96 (1H, m), 6.35 (1H, d, J=9.2 Hz), 7.28 (1H, d, J=6.4 Hz), 7.46-7.65 (6H, m), 7.71 (1H, s), 8.21 (1H, s)

MS(ESI⁺) : 386[M+H]⁺, 408[M+Na]⁺

IR(KBr) : 3382, 1662, 1602, 1444, 1191 cm⁻¹

15 mp : 225.8°C (IPA-H₂O)

Example 30

3-Amino-5-(3,5-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

20 ¹H-NMR(DMSO-d₆ δ) : 1.05 (6H, d, J=6.8 Hz), 4.95 (1H, m), 6.37 (1H, d, J=9.4 Hz), 7.14-7.37 (3H, m), 7.46 (1H, d, J=2.4Hz), 7.66 (1H, dd, J=2.4, 9.4Hz), 7.73 (3H, m), 8.23 (1H, s)

MS(ESI⁺) : 408[M+Na]⁺

IR(KBr) : 3284, 1664, 1587, 1446, 1120 cm⁻¹

25 mp : 248.8°C (IPA-H₂O)

Example 31

3-Amino-5-(4-cyanophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.98 (6H, d, $J=6.8$ Hz), 4.92 (1H, m),
5 6.35 (1H, d, $J=9.4$ Hz), 7.38 (1H, d, $J=2.4$ Hz), 7.65 (2H,
d, $J=8.4$ Hz), 7.65-7.69 (4H, m), 7.74 (1H, s), 7.90 (1H,
d, $J=8.4$ Hz), 8.24 (1H, s)

MS(ESI $^+$) : 397[M+Na] $^+$

IR(KBr) : 3432, 2223, 1671, 1606, 1450 cm^{-1}

10 mp : 292°C (IPA-H $_2$ O)

Example 32

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
5-phenyl-2-pyrazinecarbonitrile

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.94 (6H, d, $J=6.8$ Hz), 4.89 (1H, m),
15 6.35 (1H, d, $J=9.4$ Hz), 7.28 (1H, d, $J=2.4$ Hz), 7.39-7.49
(8H, m)

MS(ESI $^+$) : 332[M+H] $^+$, 354[M+Na] $^+$

IR(KBr) : 3357, 2219, 1652, 1579, 1465, 1203 cm^{-1}

mp : 205.4°C (IPA-H $_2$ O)

20 Example 33

3-Amino-5-(2-fluorophenyl)-6-(1-isopropyl-6-oxo-
1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.91 (6H, d, $J=6.8$ Hz), 4.87 (1H, m),
6.37 (1H, d, $J=9.4$ Hz), 7.18-7.63 (8H, m)

25 MS(ESI $^+$) : 350[M+H] $^+$, 372[M+Na] $^+$

IR(KBr) : 3366, 2214, 1615, 1516, 1200 cm^{-1}

mp : 210.6°C (IPA-H₂O)

Example 34

3-Amino-5-(3-fluorophenyl)-6-(1-isopropyl-6-oxo-
5 1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile

¹H-NMR(DMSO-d₆ δ) : 0.98 (6H, d, J=6.8 Hz), 4.92 (1H, m),

6.37 (1H, d, J=9.4 Hz), 7.22-7.53 (8H, m)

MS(ESI⁺) : 350[M+H]⁺, 372[M+Na]⁺

IR(KBr) : 3360, 2214, 1660, 1570, 1205 cm^{-1}

10 mp : 210.6°C (IPA-H₂O)

Example 35

3-Amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-
1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile

¹H-NMR(DMSO-d₆ δ) : 0.98 (6H, d, J=6.8 Hz), 4.92 (1H, m),

15 6.37 (1H, d, J=9.4 Hz), 7.22-7.68 (8H, m)

MS(ESI⁺) : 350[M+H]⁺

IR(KBr) : 3364, 2214, 1660, 1572, 1200 cm^{-1}

mp : 207.0°C (IPA-H₂O)

Example 36

20 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
5-(2-methoxyphenyl)-2-pyrazinecarbonitrile

¹H-NMR(DMSO-d₆ δ) : 0.97 (6H, brs), 3.46 (3H, s), 4.86 (1H,

m), 6.34 (1H, d, J=9.4 Hz), 6.99 (1H, d, 8.2 Hz), 7.10 (1H,

t, 7.6 Hz), 7.18 (1H, d, 2.5 Hz), 7.37-7.50 (5H, m)

25 MS(ESI⁺) : 362[M+H]⁺, 384[M+Na]⁺

IR(KBr) : 3266, 2214, 1600, 1448, 1255 cm^{-1}

mp : 222.6°C (IPA-H₂O)

Example 37

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5 5-(3-methoxyphenyl)-2-pyrazinecarbonitrile

¹H-NMR(DMSO-d₆ δ) : 0.98 (6H, d, J=6.8 Hz), 3.69 (3H, s),

4.91 (1H, m), 6.35 (1H, d, J=9.4 Hz), 6.95-6.97 (1H, m),

7.00 (2H, s), 7.30-7.47 (5H, m)

MS(ESI⁺) : 362[M+H]⁺, 384[M+Na]⁺

10 IR(KBr) : 3360, 2215, 1655, 1570, 1205 cm^{-1}

mp : 192.3°C (IPA-H₂O)

Example 38

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(4-methoxyphenyl)-2-pyrazinecarbonitrile

15 ¹H-NMR(DMSO-d₆ δ) : 1.02 (6H, d, J=6.8 Hz), 3.76 (3H, s),

4.93 (1H, m), 6.35 (1H, d, J=9.4 Hz), 6.98 (2H, d, 7.2Hz),

7.38-7.43 (6H, m)

MS(ESI⁺) : 362[M+H]⁺, 384[M+Na]⁺

IR(KBr) : 3357, 2218, 1650, 1570, 1200 cm^{-1}

20 mp : 243.9°C (IPA-H₂O)

Example 39

3-Amino-5-(3,4-difluorophenyl)-6-(1-isopropyl-6-oxo-

1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile

¹H-NMR(DMSO-d₆ δ) : 1.02 (6H, d, J=6.8 Hz), 4.95 (1H, m),

25 6.38 (1H, d, J=9.0 Hz), 7.26 (1H, m), 7.38-7.58 (6H, m),

MS(ESI⁺) : 368 [M+H]⁺, 390 [M+Na]⁺

IR(KBr) : 3166, 2210, 1658, 1461, 1201 cm⁻¹

mp : 180°C (IPA-H₂O)

Example 40

5 3-Amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-
1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (30 g) was
suspended in dioxane (60 ml) and 2N aq. NaOH (600 ml). The
mixture was heated at 90°C with stirring for 4 hours. The
above reaction mixture was cooled to 25-30°C. The pH of the
10 suspension was adjusted to 2.5 with 35% HCl (105 ml). The
precipitate was collected by filtration and washed with
water and dried in vacuo at 50°C for 15 hours to give
3-amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-
dihydro-3-pyridyl)-2-pyrazinecarboxylic acid as yellow
15 powder. (29.6 g)

¹H-NMR(DMSO-d₆ δ) : 1.00 (6H, d, J=6.8 Hz), 4.93 (1H, m),
6.37 (1H, d, J=9.4 Hz), 7.22-7.36 (3H, m), 7.48-7.68 (5H,
m), 13.00 (1H, s)

IR(KBr) : 3266, 1725, 1662, 1600, 1455 cm⁻¹

20 mp : 222.2°C (IPA-H₂O)

Example 41

3-Amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-
1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid (25 g)
was suspended in 1,2-dichlorobenzene (125 ml). The
25 suspension was heated at 165-170°C with stirring for 4 hours.

The reaction mixture was cooled to 20-25°C. To the cooled mixture was added IPE (250 ml). The suspension was stirred at 25-30°C for 3 hours. The precipitate was collected by filtration and dried in vacuo. The above dried precipitate
5 was purified by chromatography on silica gel (500 g) eluting with CHCl₃ : MeOH (9 : 1, 2 l). Evaporation of solvent in vacuo gave yellowish crystal residue, which was recrystallized from 70% EtOH (322 ml) to give 5-[5-amino-3-(4-fluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-
10 pyridone as yellowish crystal (19.4 g).

¹H-NMR(DMSO-d₆ δ) : 1.00 (6H, d, J=6.8 Hz), 4.93 (1H, m), 6.33 (1H, d, J=9.2 Hz), 6.63 (2H, s), 7.17-7.26 (3H, m), 7.38-7.46 (3H, m), 7.93 (1H, s)

MS(ESI⁺) : 325[M+H]⁺, 347[M+Na]⁺

15 IR(KBr) : 3166, 1666, 1604, 1533, 1467, 1222 cm⁻¹
mp : 257.7°C (IPA-H₂O)

Example 42

A mixture of 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid
20 (70 mg), methylamine hydrochloride (14.8 mg), 1-ethyl-3-[3'-(dimethylamino)propyl]-carbodiimide (34.1 mg), and 1-hydroxy-benzotriazole (29.7 mg) in CH₂Cl₂ (0.7 ml) was stirred at 25°C for 4 hours. Water and EtOAc were poured into the mixture. The organic layer was separated,
25 washed with water, sat. aq. NaHCO₃, and brine, and dried

over MgSO_4 . The solvent was removed under reduced pressure. The residue was purified by silica-gel column chromatography (*n*-hexane - EtOAc then CH_2Cl_2 - MeOH) and then crystallized from MeOH-IPE to give

5 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-N-methyl-5-phenyl-2-pyrazinecarboxamide (40 mg).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.93 (6H, d, $J=6.8$ Hz), 2.84 (3H, d, $J=4.8$ Hz), 4.89 (1H, qq, $J=6.8, 6.8$ Hz), 6.38 (1H, d, $J=9.4$ Hz), 7.26 (1H, d, $J=2.5$ Hz), 7.42 (5H, m), 7.62 (2H, brs), 7.79 (1H, dd, $J=2.5, 9.4$ Hz), 8.69 (1H, m)

MS(ESI $^+$) : 364[M+H] $^+$

The following 4 compounds were obtained in a similar manner to that of Example 42.

15 Example 43

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-N,N-dimethyl-5-phenyl-2-pyrazinecarboxamide

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.93 (6H, d, $J=6.7$ Hz), 3.04 (3H, s), 3.10 (3H, s), 4.89 (1H, qq, $J=6.7, 6.7$ Hz), 6.36 (1H, d, $J=9.4$ Hz), 6.73 (2H, brs), 7.21 (1H, d, $J=2.5$ Hz), 7.3-7.6 (6H, m)

MS(ESI $^-$) : 376[M-H] $^-$

Example 44

5-[5-Amino-6-(4-morpholinylcarbonyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.95 (6H, d, $J=6.8$ Hz), 3.63 (4H, brs),
3.70 (4H, brs), 4.86 (1H, qq, $J=6.8$, 6.8 Hz), 6.36 (1H, d,
 $J=9.4$ Hz), 6.78 (2H, brs), 7.24 (1H, d, $J=2.4$ Hz), 7.3-7.5
(6H, m)

5 MS(ESI $^+$) : 420[M+H] $^+$

Example 45

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
5-phenyl-N-(2-pyridylmethyl)-2-pyrazinecarboxamide

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.94 (6H, d, $J=6.8$ Hz), 4.64 (2H, d,
10 $J=6.0$ Hz), 4.87 (1H, qq, $J=6.8$, 6.8 Hz), 6.39 (1H, d, $J=9.4$
Hz), 7.1-7.9 (12H, m), 8.52 (1H, distorted d, $J=4.1$ Hz),
9.37 (1H, t, $J=6.0$ Hz).

MS(ESI $^+$) : 441[M+H] $^+$

Example 46

15 3-Amino-N-(cyanomethyl)-6-(1-isopropyl-6-oxo-
1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide.

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.92 (6H, d, $J=6.8$ Hz), 4.34 (2H, d,
 $J=5.9$ Hz), 4.88 (1H, qq, $J=6.8$, 6.8 Hz), 6.41 (1H, d, $J=9.4$
Hz), 7.24 (1H, d, $J=2.4$ Hz), 7.3-7.5 (5H, m), 7.61 (2H, brs),
20 7.83 (1H, dd, $J=2.4$, 9.4 Hz), 9.27 (1H, brt, $J=5.9$ Hz)

MS(ESI $^+$) : 389[M+H] $^+$, 411[M+Na] $^+$

Example 47

To a mixture of 3-amino-6-(1-isopropyl-6-oxo-
1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic
25 acid (70 mg) and NEt_3 (40.4 mg) in THF (0.7 ml), was added

isobutyl chloroformate (32.7 mg) under ice-bath cooling. After 1.5 hours stirring at the same temperature, the mixture was poured into a mixture of sodium borohydride (30.2 mg) in a mixture of THF (0.7 ml) and water (1.4 ml) under ice-bath cooling. After 2.5 hours stirring at the same temperature, the mixture was diluted with water and EtOAc, and then the organic layer was separated, washed with water and brine, and dried over MgSO_4 . The solvent was removed under reduced pressure. The residue was purified by silica-gel column chromatography (CH_2Cl_2 : MeOH=25 : 1 - 10 : 1). A desired fraction was triturated with IPE to give 5-[5-amino-6-(hydroxymethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (24 mg).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.95 (6H, d, $J=6.8$ Hz), 4.59 (2H, d, $J=5.6$ Hz), 4.90 (1H, qq, $J=6.8$, 6.8 Hz), 5.34 (1H, t, $J=5.6$ Hz), 6.3-6.4 (3H, m), 7.20 (1H, d, $J=2.4$ Hz), 7.2-7.5 (5H, m), 7.50 (1H, dd, $J=2.4$, 9.4 Hz)

MS(ESI $^+$) : 337[M+H] $^+$, 359[M+Na] $^+$

The following 3 compounds were obtained in a similar manner to that of Example 42.

Example 48

5-[5-Amino-6-(1-azetidinylicarbonyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.92 (6H, d, $J=6.8$ Hz), 2.25 (2H, m), 4.09 (2H, t, $J=7.6$ Hz), 4.70 (2H, t, $J=7.6$ Hz), 4.91 (1H,

qq, J=6.8, 6.8 Hz), 6.36 (1H, d, J=9.4 Hz), 7.29 (1H, d, J=2.4 Hz), 7.3-7.6 (6H, m), 7.62 (2H, brs)

MS(ESI⁺) : 390[M+H]⁺

Example 49

5 3-Amino-N-(2-hydroxyethyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 0.93 (6H, d, J=6.8 Hz), 3.4-3.5 (2H, m), 3.5-3.6 (2H, m), 4.7-5.0 (2H, m), 6.39 (1H, d, J=9.4 Hz), 7.26 (1H, 2.4 Hz), 7.3-7.5 (5H, m), 7.63 (2H, brs),

10 7.75 (1H, dd, J=2.4, 9.4 Hz), 8.63 (1H, t, J=5.8 Hz)

MS(ESI⁺) : 394[M+H]⁺, 416[M+Na]⁺

Example 50

3-Amino-N-cyclopropyl-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide

15 ¹H-NMR(DMSO-d₆ δ) : 0.6-0.8 (4H, m), 0.93 (6H, d, J=6.8 Hz), 2.84 (1H, m), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.37 (1H, d, J=9.4 Hz), 7.29 (1H, d, J=2.4 Hz), 7.3-7.5 (5H, m), 7.61 (2H, brs), 7.75 (1H, dd, J=2.4, 9.4 Hz), 8.57 (1H, t, J=4.2 Hz)

20 MS(ESI⁺) : 390[M+H]⁺, 412[M+Na]⁺

Example 51

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid

The title compound was obtained in a similar manner
25 to that of Example 40.

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.95 (6H, d, $J=6.8$ Hz), 4.90 (1H, qq, $J=6.8$, 6.8 Hz), 6.37 (1H, d, $J=9.4$ Hz), 7.31 (1H, d, $J=2.4$ Hz), 7.2-7.6 (7H, m), 7.59 (1H, dd, $J=2.4$, 9.4 Hz), 13.0 (1H, brs)

5 MS(ESI $^-$) : 349[M-H] $^-$

Example 52

5-(5-Amino-3-phenyl-2-pyrazinyl)-1-isopropyl-
2(1H)-pyridone

The title compound was obtained in a similar manner
10 to that of Example 41.

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.95 (6H, d, $J=6.8$ Hz), 4.90 (1H, qq, $J=6.8$, 6.8 Hz), 6.32 (1H, d, $J=9.4$ Hz), 6.60 (2H, brs), 7.21 (1H, d, $J=2.4$ Hz), 7.2-7.5 (6H, m), 7.93 (1H, s)

MS(ESI $^+$) : 307[M+H] $^+$, 329[M+Na] $^+$

15 Example 53

A mixture of 5-(5-amino-3-phenyl-2-pyrazinyl)-
1-isopropyl-2(1H)-pyridone (100 mg) and
N-bromosuccinimide (87.1 mg) in DMF was heated at 50°C with
stirring for 20 minutes. Sat. aq. NaHCO $_3$ and EtOAc were
20 poured into the mixture. The organic layer was separated,
washed with water and brine, and dried over MgSO $_4$. The
solvent was removed under reduced pressure. The residue was
purified by silica gel column chromatography (n -hexane :
EtOAc=10 : 1 - 2 : 1). A desired product was recrystallized
25 with IPE and dried in vacuo to give

5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-3-bromo-
1-isopropyl-2(1H)-pyridone (57 mg).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.94 (6H, d, $J=6.8$ Hz), 4.89 (1H, qq,
 $J=6.8$, 6.8 Hz), 6.97 (2H, brs), 7.24 (1H, d, $J=2.4$ Hz),
5 7.2-7.6 (5H, m), 7.92 (1H, d, $J=2.4$ Hz)

MS(ESI $^+$) : 463[M+H] $^+$

Example 54

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
N-methoxy-N-methyl-5-phenyl-2-pyrazinecarboxamide

10 The title compound was obtained in a similar manner
to that of Example 42.

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.94 (6H, d, $J=6.8$ Hz), 3.36 (3H, s),
3.75 (3H, s), 4.89 (1H, qq, $J=6.8$, 6.8 Hz), 6.36 (1H, d,
 $J=9.3$ Hz), 6.79 (2H, brs), 7.24 (1H, d, $J=2.4$ Hz), 7.3-7.6
15 (6H, m)

MS(ESI $^+$) : 394[M+H] $^+$

Example 55

5-(5-Amino-6-chloro-3-phenyl-2-pyrazinyl)-3-chloro-
1-isopropyl-2(1H)-pyridone

20 The title compound was obtained in a similar manner
to that of Example 53.

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.95 (6H, d, $J=6.8$ Hz), 4.90 (1H, qq,
 $J=6.8$, 6.8 Hz), 7.05 (2H, brs), 7.22 (1H, d, $J=2.4$ Hz),
7.2-7.6 (5H, m), 7.74 (1H, d, $J=2.4$ Hz)

25 MS(ESI $^+$) : 375[M+H] $^+$, 397[M+Na] $^+$

Example 56

5-([5-Amino-6-[(3-methoxy-1-azetidinyl)carbonyl]-
3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone

The title compound was obtained in a similar manner
5 to that of Example 1.

¹H-NMR(DMSO-d₆ δ) : 1.00 (6H, d, J=6.8 Hz), 3.24 (3H, s),
3.8-4.0 (1H, m), 4.2-4.5 (2H, m), 4.4-4.6 (1H, m), 4.8-5.1
(2H, m), 6.35 (1H, J=9.2 Hz), 7.3-7.5 (7H, m), 7.62 (2H,
brs)

10 MS(ESI⁺) : 420[M+H]⁺

Example 57

Under ice-bath cooling, to a suspension of
3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
N-methoxy-N-methyl-5-phenyl-2-pyrazinecarboxamide (200
15 mg) in THF (4.0 ml) was added 3.0M solution of
methylmagnesium chloride in THF (0.85 ml) dropwise. The
mixture was stirred at the same temperature for 5 hours.
The mixture was poured into sat. aq ammonium chloride (20
ml) and an organic layer was extracted with EtOAc (50 ml),
20 washed with water and brine, and dried over MgSO₄. The
solvent was removed under reduced pressure. The residue was
purified by silica-gel column chromatography (CH₂Cl₂ :
MeOH=50 : 1 - 15 : 1). The desired fraction was
recrystallized from MeOH and dried in vacuo to give
25 5-(6-acetyl-5-amino- 3-phenyl-2-pyrazinyl)-1-isopropyl-

2(1H)-pyridone (111 mg).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.95 (6H, d, $J=6.8$ Hz), 2.66 (3H, s),
4.91 (1H, qq, $J=6.8$, 6.8 Hz), 6.41 (1H, d, $J=9.4$ Hz), 7.30
(1H, d, $J=2.4$ Hz), 7.3-7.6 (5H, m), 7.61 (1H, dd, $J=2.4$,
5 9.4 Hz), 7.81 (2H, brs)

MS(ESI $^+$) : 249[M+H] $^+$, 371[M+Na] $^+$

Example 58

3-Amino-N-[2-(dimethylamino)ethyl]-6-(1-isopropyl-
6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-

10 2-pyrazinecarboxamide

The title compound was obtained in a similar manner
to that of Example 42.

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.97 (6H, d, $J=6.8$ Hz), 2.20 (6H, s),
2.42 (2H, t, $J=6.6$ Hz), 3.3-3.5 (2H, m), 4.91 (1H, qq, $J=6.8$,
15 6.8 Hz), 6.37 (1H, d, $J=9.4$ Hz), 7.31 (1H, d, $J=2.4$ Hz),
7.3-7.5 (5H, m), 7.66 (1H, dd, $J=2.4$, 9.4 Hz), 8.62 (1H,
t, $J=5.7$ Hz)

MS(ESI $^+$) : 421[M+H] $^+$

Example 59

20 3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-
5-phenyl-2-pyrazinecarbonitrile

The title compound was obtained in a similar manner
to that of Example 1.

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 3.40 (3H, s), 6.17 (1H, d, $J=9.4$ Hz),
25 6.97 (1H, dd, $J=2.6$, 9.4 Hz), 7.40-7.49 (7H, m), 7.81 (1H,

d, $J=2.6$ Hz)

MS (ESI⁺) : 304 [M+H]⁺, 326 [M+Na]⁺

IR (KBr) : 3386, 2221, 1670, 1590, 1542, 1205 cm⁻¹

Example 60

- 5 A mixture of 3-amino-5-chloro-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (500 mg), (4-methoxyphenyl)boronic acid (740 mg), and Pd(PPh₃)₄ (56.3 mg) in 2M aq. Na₂CO₃ (3.25 ml) and dioxane (20 ml) was refluxed for 3 hours. Water (40 ml) and of EtOAc (30 ml) were poured into the reaction mixture and the aqueous solution was extracted with EtOAc. The organic layer was washed with water and brine, and dried over MgSO₄. After filtration, the solvent was removed under reduced pressure. The residual solid was placed on a column of silica-gel and eluted with CHCl₃ : MeOH (25 : 1). The eluent was evaporated and the residue was suspended with IPE and filtrated to give 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(4-methoxyphenyl)-2-pyrazinecarboxamide (512 mg) as a yellow powder.
- 10
- 20 ¹H-NMR (DMSO-d₆ δ) : 1.05 (6H, d, $J=7.0$ Hz), 4.94 (1H, sept, $J=7.0$ Hz), 6.32 (1H, d, $J=9.5$ Hz), 6.98 (2H, d, $J=9.0$ Hz), 7.39-7.64 (7H, m), 8.15 (1H, brs).
- MS (ESI⁺) : 380 [M+H]⁺, 421 [M+H+MeCN]⁺
- The following 18 compounds were obtained in a similar manner
- 25 to that of Example 60.

Example 61

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
5- (2-methoxyphenyl)-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 0.89 (6H, brs), 3.48 (3H, s), 4.88 (1H,
5 sept, J=6.8 Hz), 6.32 (1H, d, J=9.5 Hz), 7.00-7.13 (2H, m),
7.22 (1H, d, J=2.5 Hz), 7.37-7.79 (6H, m), 8.16 (1H, brs)

Example 62

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
5-(3-methoxyphenyl)-2-pyrazinecarboxamide

10 ¹H-NMR(DMSO-d₆ δ) : 1.00 (6H, d, J=7.0 Hz), 3.71 (3H, s),
4.92 (1H, sept, J=7.0 Hz), 6.33 (1H, d, J=9.5 Hz), 6.94-7.02
(3H, m), 7.30-7.39 (2H, m), 7.65-7.71 (4H, m), 8.20 (1H,
brs)

Example 63

15 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
5-(2-methylphenyl)-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 0.88 (6H, d, J=7.0 Hz), 1.99 (3H, s),
4.85 (1H, sept, J=7.0 Hz), 6.33 (1H, d, J=9.5 Hz), 7.11 (1H,
d, J=2.5 Hz), 7.32 (4H, brs), 7.70 (3H, brs), 7.89 (1H, dd,
20 J=2.5, 9.5 Hz), 8.23 (1H, brs)

MS(ESI⁺) : 364 [M+H]⁺, 405 [M+H+MeCN]⁺

Example 64

3-Amino-5-(2,3-difluorophenyl)-6-(1-isopropyl-6-oxo-
1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

25 ¹H-NMR(DMSO-d₆ δ) : 0.97 (6H, d, J=7.0 Hz), 4.92 (1H, sept,

J=7.0 Hz), 6.37 (1H, d, J=9.0 Hz), 7.34-7.79 (8H, m), 8.26 (1H, brs)

MS(ESI⁺) : 386[M+H]⁺, 427[M+H+MeCN]⁺

Example 65

5 3-Amino-5-(2,4-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 0.99 (6H, d, J=6.8 Hz), 4.93 (1H, sept, J=6.8 Hz), 6.36 (1H, d, J=9.0 Hz), 7.24-7.35 (3H, m), 7.65-7.77 (5H, m), 8.23 (1H, brs)

10 MS(ESI⁺) : 386[M+H]⁺, 427[M+H+MeCN]⁺

Example 66

3-Amino-5-(2,5-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 0.99 (6H, d, J=7.0 Hz), 4.92 (1H, sept, J=7.0 Hz), 6.37 (1H, d, J=9.5 Hz), 7.24-7.40 (3H, m), 7.48-7.79 (5H, m), 8.25 (1H, brs)

MS(ESI⁺) : 386[M+H]⁺, 427[M+H+MeCN]⁺

Example 67

20 3-Amino-5-(2-furyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 1.25 (6H, d, J=6.8 Hz), 5.07 (1H, sept, J=6.8 Hz), 6.39 (1H, d, J=9.0 Hz), 6.61 (1H, dd, J=1.1, 3.5 Hz), 6.79 (1H, d, J=3.5 Hz), 7.55 (1H, dd, J=2.5, 9.5 Hz), 7.66 (3H, brs), 7.79 (2H, brs), 8.09 (1H, brs)

25 MS(ESI⁺) : 340[M+H]⁺, 381[M+H+MeCN]⁺

Example 68

3-Amino-5-(3-furyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 1.25 (6H, d, J=6.8 Hz), 5.07 (1H, sept, J=6.8 Hz), 6.39 (1H, d, J=9.0 Hz), 6.62 (1H, dd, J=2.0, 3.5 Hz), 6.79 (1H, d, J=3.5 Hz), 7.55 (1H, dd, J=2.5, 9.5 Hz), 7.66 (3H, brs), 7.99 (2H, s), 8.09 (1H, brs)

MS(ESI⁺) : 340[M+H]⁺, 381[M+H+MeCN]⁺

Example 69

10 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-thienyl)-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 1.23 (6H, d, J=6.8 Hz), 5.07 (1H, sept, J=6.8 Hz), 6.42 (1H, d, J=9.5 Hz), 7.04-7.06 (1H, m), 7.16-7.17 (1H, m), 7.49 (1H, d, J=2.5 Hz), 7.54 (1H, d, J=2.5 Hz), 7.65 (2H, brs), 7.69 (1H, d, J=5.5 Hz), 7.87 (1H, d, J=2.5 Hz), 8.06 (1H, brs)

MS(ESI⁺) : 356[M+H]⁺, 397[M+H+MeCN]⁺

Example 70

20 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(3-thienyl)-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 1.12 (6H, d, J=7.0 Hz), 4.98 (1H, sept, J=7.0 Hz), 6.36 (1H, d, J=9.0 Hz), 7.12 (1H, dd, J=1.3, 5.0 Hz), 7.54-7.71 (7H, m), 8.14 (1H, brs)

MS(ESI⁺) : 356[M+H]⁺, 397[M+H+MeCN]⁺

25 Example 71

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(5-methyl-2-thienyl)-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 1.26 (6H, d, J=6.5 Hz), 2.44 (3H, s),
5.08 (1H, sept, J=6.8 Hz), 6.41 (1H, d, J=9.5 Hz), 6.76 (1H,
5 d, J=2.5 Hz), 6.98 (1H, d, J=3.5 Hz), 7.47 (1H, d, J=2.5
Hz), 7.52 (1H, d, J=2.5 Hz), 7.61 (2H, brs), 7.89 (1H, d,
J=2.5 Hz), 8.01 (1H, brs)

MS(ESI⁺) : 370[M+H]⁺, 411[M+H+MeCN]⁺

Example 72

10 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(1H-pyrazol-4-yl)-2-pyrazinecarboxamide

¹H-NMR(DMSO-d₆ δ) : 1.23 (6H, d, J=7.0 Hz), 5.06 (1H, sept,
J=7.0 Hz), 6.40 (1H, d, J=9.5 Hz), 7.50 (1H, dd, J=2.5, 9.5
Hz), 7.57 (5H, brs), 7.80 (1H, d, J=2.5 Hz), 8.01 (1H, brs),
15 13.06 (1H, brs)

MS(ESI⁺) : 362[M+Na]⁺, 701[2M+Na]⁺

Example 73

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-[(E)-2-phenylvinyl]-2-pyrazinecarboxamide

20 ¹H-NMR(DMSO-d₆ δ) : 1.32 (6H, d, J=6.5 Hz), 5.12 (1H, sept,
J=6.5 Hz), 6.50 (1H, d, J=9.5 Hz), 7.20-7.43 (5H, m),
7.59-7.83 (6H, m), 7.90 (1H, d, J=2.5 Hz), 8.10 (1H, brs)

MS(ESI⁺) : 398[M+Na]⁺, 773[2M+Na]⁺

Example 74

25 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(3-pyridyl)-2-pyrazinecarboxamide

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.98 (6H, d, $J=7.0$ Hz), 4.93 (1H, sept, $J=7.0$ Hz), 6.36 (1H, d, $J=9.5$ Hz), 7.37-7.46 (3H, m), 7.66-7.75 (4H, m), 8.26 (1H, brs), 8.61-8.64 (2H, m)

5 MS(ESI $^+$) : 351[M+H] $^+$, 392[M+H+MeCN] $^+$

Example 75

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(4-pyridyl)-2-pyrazinecarboxamide

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.00 (6H, d, $J=7.0$ Hz), 4.93 (1H, sept, $J=7.0$ Hz), 6.35 (1H, d, $J=9.5$ Hz), 7.42-7.89 (7H, m), 8.23 (1H, brs), 8.57 (1H, dd, $J=2.0, 5.0$ Hz), 8.64 (1H, d, $J=2.0$ Hz)

MS(ESI $^+$) : 351[M+H] $^+$, 392[M+H+MeCN] $^+$

Example 76

15 3-Amino-5-(4-fluorophenyl)-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 3.46 (3H, s), 6.17 (1H, d, $J=9.5$ Hz), 7.00 (1H, dd, $J=2.5, 9.5$ Hz), 7.25 (2H, t, $J=9$ Hz), 7.51-7.73 (5H, m), 8.15 (1H, d, $J=2.5$ Hz), 8.27 (1H, brs)

20 MS(ESI $^+$) : 362[M+Na] $^+$, 701[2M+Na] $^+$

Example 77

3-Amino-5-(2-furyl)-6-(1-methyl-6-oxo-1,6-dihydro-

3-pyridyl)-2-pyrazinecarboxamide

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 3.50 (3H, s), 6.33 (1H, d, $J=9.0$ Hz), 6.63 (1H, dd, $J=1.8, 3.5$ Hz), 6.83 (1H, d, $J=3.5$ Hz), 7.28 .

(1H, dd, J=2.5, 9.5 Hz), 7.69-7.79 (4H, m), 8.10 (1H, d, J=2.5 Hz), 8.16 (1H, brs)

MS (ESI⁺) : 334[M+Na]⁺

Example 78

5 3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-
5-(2-thienyl)-2-pyrazinecarboxamide

¹H-NMR (DMSO-d₆ δ) : 3.50 (3H, s), 6.35 (1H, d, J=9.5 Hz),
7.04-7.09 (1H, m), 7.19-7.21 (1H, m), 7.35 (1H, dd, J=2.5,
9.5 Hz), 7.66 (1H, brs), 7.70-7.72 (3H, m), 8.12-8.13 (2H,
10 m)

MS (ESI⁺) : 350[M+Na]⁺

Example 79

A mixture of 3-amino-5-chloro-6-(1-isopropyl-6-oxo-
1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (200 mg),
15 ethynylbenzen (331 mg), NEt₃ (658 mg), triphenylphosphine
(17 mg), CuI (6.2 mg), and PdCl₂(PPh₃)₂ (23 mg) in DMF (2
ml) was heated at 80°C for 18 hours. Water (20 ml) and EtOAc
(20 ml) were poured into the reaction mixture and the
aqueous solution was extracted with EtOAc. The organic
20 layer was washed with water and brine, and dried over MgSO₄.
After filtration, the solvent was removed under reduced
pressure. The residual solid was placed on a column of
silica-gel and eluted with CHCl₃-MeOH (97 : 3). The eluent
was evaporated and the residue was suspended with IPE and
25 filtrated to give 3-amino-6-(1-isopropyl-6-oxo-

1,6-dihydro-3-pyridyl)-5-(phenylethynyl)-
2-pyrazinecarboxamide (218 mg) as a yellow powder.
MS (ESI⁺) : 396[M+Na]⁺, 769[2M+Na]⁺

Example 80

5 A toluene solution of 3-amino-5-chloro-
6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
2-pyrazinecarboxamide (200 mg),
2-(tributylstannyl)pyridine (311 mg), and Pd(PPh₃)₄ (22.5
mg) was refluxed for 5 hours. Water (20 ml) and EtOAc (15
10 ml) were poured into the reaction mixture and the aqueous
solution was extracted with EtOAc. The organic layer was
washed with water and brine, and dried over MgSO₄. After
filtration, the solvent was removed under reduced pressure.
The residual solid was placed on a column of silica-gel and
15 eluted with CHCl₃ - MeOH (97 : 3). The eluent was evaporated
and the residue was suspended with IPE and filtrated to give
3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
5-(2-pyridyl)-2-pyrazinecarboxamide (64 mg) as a yellow
powder.
20 ¹H-NMR (DMSO-d₆ δ) : 1.01 (6H, d, J=6.5 Hz), 4.93 (1H, sept,
J=6.5 Hz), 6.30 (1H, d, J=9.5 Hz), 7.35-7.46 (2H, m),
7.59-7.75 (5H, m), 7.96 (1H, dt, J=1.7, 7.8 Hz), 8.24 (1H,
brs), 8.55 (1H, d, J=4.5 Hz)
MS (ESI⁺) : 351[M+H]⁺

25 Example 81

- To a suspension of 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(4-methoxyphenyl)-2-pyrazinecarboxamide (210 mg) in dioxane (2 ml) was added an aq. NaOH (2M, 4 ml) and this solution was heated at 100°C for 4 hours. This reaction mixture was cooled to room temperature and the pH of this solution was adjusted to 2.5 with 2N aq. HCl. The precipitate was collected by filtration and washed with water to give 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(4-methoxyphenyl)-2-pyrazinecarboxylic acid (203 mg) as a yellow powder.
- ¹H-NMR(DMSO-d₆ δ) : 1.03 (1H, d, J=7 Hz), 3.77 (3H, s), 4.94 (1H, sept, J=7.0 Hz), 6.36 (1H, d, J=9.5 Hz), 6.98 (2H, d, J=9.0 Hz), 7.41-7.56 (6H, m), 12.91 (1H, brs)
- MS(ESI⁺) : 381[M+H]⁺, 422[M+H+MeCN]⁺
- The following 24 compounds were obtained in a similar manner to that of Example 81.

Example 82

- 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-methoxyphenyl)-2-pyrazinecarboxylic acid
- ¹H-NMR(DMSO-d₆ δ) : 0.91 (6H, brs), 3.48 (3H, s), 4.87 (1H, sept, J=6.8 Hz), 6.35 (1H, d, J=9.5 Hz), 7.01 (1H, d, J=8 Hz), 7.10 (1H, t, J=7.5 Hz), 7.19 (1H, d, J=2.5 Hz), 7.38-7.49 (4H, m), 7.62 (1H, dd, J=2.5, 9.0 Hz), 12.93 (1H, brs)
- MS(ESI⁺) : 381[M+H]⁺, 422[M+H+MeCN]⁺

Example 83

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
5-(3-methoxyphenyl)-2-pyrazinecarboxylic acid

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.99 (6H, d, $J=7$ Hz), 3.70 (3H, s), 4.92
5 (1H, sept, $J=7.0$ Hz), 6.37 (1H, d, $J=9.5$ Hz), 6.95-7.04 (3H,
m), 7.30-7.38 (2H, m), 7.50 (2H, brs), 7.58 (1H, dd, $J=2.5$,
9.0 Hz), 13 (1H, brs)

MS (ESI $^+$) : 381[M+H] $^+$, 422[M+H+MeCN] $^+$

Example 84

10 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
5-(2-methylphenyl)-2-pyrazinecarboxylic acid

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.88 (6H, d, $J=7.0$ Hz), 1.99 (3H, s),
4.85 (1H, t, $J=7.0$ Hz), 6.37 (1H, d, $J=9.5$ Hz), 7.09 (1H,
d, $J=2.5$ Hz), 7.26 - 7.40 (4H, m), 7.49 (2H, brs), 7.73 (1H,
15 dd, $J=2.5$, 9.5 Hz), 13.05 (1H, brs)

Example 85

3-Amino-5-(2,3-difluorophenyl)-6-(1-isopropyl-6-oxo-
1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.95 (6H, d, $J=3.5$ Hz), 4.92 (1H, sept,
20 $J=3.5$ Hz), 6.40 (1H, d, $J=4.7$ Hz), 7.30 (1H, d, $J=1.1$ Hz),
7.34-7.63 (6H, m), 13.20 (1H, brs)

MS (ESI $^+$) : 387[M+H] $^+$, 428[M+H+MeCN] $^+$

Example 86

3-Amino-5-(2,4-difluorophenyl)-6-(1-isopropyl-6-oxo-
25 1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.97 (6H, d, $J=3.4$ Hz), 4.92 (1H, sept, $J=3.4$ Hz), 6.39 (1H, d, $J=4.8$ Hz), 7.26-7.33 (3H, m), 7.56 (2H, brs), 7.61 (1H, dd, $J=1.3, 4.8$ Hz), 7.68-7.74 (1H, m), 13.15 (1H, brs)

5 MS (ESI $^+$) : 387[M+H] $^+$, 428[M+H+MeCN] $^+$

Example 87

3-Amino-5-(2,5-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.97 (6H, d, $J=3.5$ Hz), 4.92 (1H, sept, $J=3.5$ Hz), 6.4 (1H, d, $J=4.8$ Hz), 7.25-7.38 (3H, m), 7.51-7.55 (1H, m), 7.58 (2H, brs), 7.62 (1H, dd, $J=1.3, 4.8$ Hz), 13.19 (1H, brs)

MS (ESI $^+$) : 387[M+H] $^+$, 428[M+H+MeCN] $^+$

Example 88

15 3-Amino-5-(2-furyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.24 (6H, d, $J=6.5$ Hz), 5.09 (1H, sept, $J=6.5$ Hz), 6.43 (1H, d, $J=9$ Hz), 6.62 (1H, dd, $J=2, 3.5$ Hz), 6.77 (1H, d, $J=3$ Hz), 7.45-7.51 (3H, m), 7.75-7.82 (2H, m)

20 Example 89

3-Amino-5-(3-furyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.21 (6H, d, $J=3.5$ Hz), 5.06 (1H, sept, $J=3.5$ Hz), 6.43 (1H, d, $J=4.8$ Hz), 6.54 (1H, d, $J=0.9$ Hz), 7.44 (2H, brs), 7.48 (1H, dd, $J=1.3, 4.8$ Hz), 7.72-7.77 (3H,

m), 12.95 (1H, brs)

MS(ESI⁺) : 341[M+H]⁺, 382[M+H+MeCN]⁺

Example 90

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5 5-(2-thienyl)-2-pyrazinecarboxylic acid

¹H-NMR(DMSO-d₆ δ) : 1.22 (6H, d, J=7.0 Hz), 5.08 (1H, sept, J=7.0 Hz), 6.46 (1H, d, J=9.0 Hz), 7.05-7.09 (1H, m), 7.2 (1H, dd, J=1.0, 4.0 Hz), 7.42-7.48 (3H, m), 7.73 (1H, dd, J=1.0, 5.0 Hz), 7.83 (1H, d, J=2.5 Hz), 13.00 (1H, brs)

10 MS(ESI⁺) : 357[M+H]⁺, 398[M+H+MeCN]⁺

Example 91

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(3-thienyl)-2-pyrazinecarboxylic acid

¹H-NMR(DMSO-d₆ δ) : 1.10 (6H, d, J=6.5 Hz), 4.98 (1H, sept, J=6.5 Hz), 6.37-6.43 (1H, m), 7.13 (1H, dd, J=1.5, 5.0 Hz), 15 7.46-7.60 (5H, m), 7.72 (1H, dd, J=1.3, 3 Hz)

MS(ESI⁺) : 357[M+H]⁺, 398[M+H+MeCN]⁺

Example 92

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

20 5-(5-methyl-2-thienyl)-2-pyrazinecarboxylic acid

¹H-NMR(DMSO-d₆ δ) : 1.25 (6H, d, J=7.0 Hz), 5.09 (1H, sept, J=7.0 Hz), 2.44 (3H, s), 6.45 (1H, d, J=9.5 Hz), 6.77-6.78 (1H, m), 7.01 (1H, d, J=3.5 Hz), 7.40-7.46 (3H, m), 7.85 (1H, d, J=2.5 Hz), 12.98 (1H, brs)

25 MS(ESI⁺) : 371[M+H]⁺, 412[M+H+MeCN]⁺

Example 93

3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(1H-pyrazol-4-yl)-2-pyrazinecarboxylic acid

 $^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.23 (1H, d, $J=7.0$ Hz), 5.07 (1H, sept,5 $J=7.0$ Hz), 6.44 (1H, d, $J=9.0$ Hz), 7.37 (2H, brs), 7.43 (1H,dd, $J=2.5$, 9.0 Hz), 7.66 (2H, s), 7.77 (1H, d, $J=2.5$ Hz),

12.99 (1H, brs).

MS(ESI $^-$) : 339[M-H] $^-$ Example 94

10 3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-[(E)-2-phenylvinyl]-2-pyrazinecarboxylic acid

MS(ESI $^-$) : 375[M-H] $^-$ Example 95

3-Amino-5-(4-fluorophenyl)-6-(1-methyl-6-oxo-1,6-

15 dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

 $^1\text{H-NMR}$ (DMSO- d_6 δ) : 3.43 (3H, s), 6.22 (1H, d, $J=9.5$ Hz),7.05 (1H, dd, $J=2.8$, 9.5 Hz), 7.26 (2H, t, $J=8.8$ Hz), 7.50(2H, brs), 7.55 (2H, dd, $J=5.5$, 9.0 Hz), 7.92 (1H, d, $J=2.5$

Hz)

20 Example 96

3-Amino-5-(2-furyl)-6-(1-methyl-6-oxo-1,6-dihydro-

3-pyridyl)-2-pyrazinecarboxylic acid

MS(ESI $^-$) : 311[M-H] $^-$ Example 97

25 3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(2-thienyl)-2-pyrazinecarboxylic acid

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 3.49 (3H, s), 6.40 (1H, d, $J=9.5$ Hz),
7.08 (1H, dd, $J=4.0, 5.0$ Hz), 7.22 (1H, dd, $J=1.0, 4.0$ Hz),
7.36 (1H, dd, $J=2.8, 9.5$ Hz), 7.48 (2H, brs), 7.74 (1H, dd,
5 $J=1.0, 5.0$ Hz), 7.97 (1H, d, $J=2.5$ Hz)

Example 98

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-
5-(phenylethynyl)-2-pyrazinecarboxylic acid

MS (ESI $^-$) : 373[M-H] $^-$

10 Example 99

3-Amino-5-(2-fluorophenyl)-6-(1-isopropyl-6-oxo-
1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.92 (1H, d, $J=7.0$ Hz), 4.88 (1H, sept,
 $J=7.0$ Hz), 6.38 (1H, d, $J=9.5$ Hz), 7.18-7.69 (8H, m), 13.12
15 (1H, brs)

MS (ESI $^+$) : 369[M+H] $^+$, 410[M+H+MeCN] $^+$

Example 100

3-Amino-5-(3-fluorophenyl)-6-(1-isopropyl-6-oxo-
1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

20 $^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.99 (6H, d, $J=6.5$ Hz), 4.93 (1H, t,
 $J=6.5$ Hz), 6.38 (1H, d, $J=9.0$ Hz), 7.22-7.60 (8H, m), 13.07
(1H, brs)

MS (ESI $^+$) : 369[M+H] $^+$, 410[M+H+MeCN] $^+$

Example 101

25 3-Amino-5-(3-chlorophenyl)-6-(1-isopropyl-6-oxo-

1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.99 (1H, d, $J=7.0$ Hz), 4.94 (1H, sept, $J=7.0$ Hz), 6.39 (1H, d, $J=9.5$ Hz), 7.37-7.62 (8H, m), 13.06 (1H, brs)

5 MS(ESI $^+$) : 385[M+H] $^+$, 426[M+H+MeCN] $^+$

Example 102

3-Amino-5-(4-chlorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.00 (6H, d, $J=7.0$ Hz), 4.94 (1H, t, $J=7.0$ Hz), 6.38 (1H, d, $J=9.5$ Hz), 7.34-7.59 (8H, m), 13.04 (1H, brs)

MS(ESI $^+$) : 385[M+H] $^+$, 426[M+H+MeCN] $^+$

Example 103

3-Amino-5-(3,4-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.03 (6H, d, $J=7.0$ Hz), 4.96 (1H, sept, $J=6.8$ Hz), 6.39 (1H, d, $J=9.0$ Hz), 7.30-7.61 (7H, m), 13.06 (1H, brs)

MS(ESI $^+$) : 387[M+H] $^+$, 428[M+H+MeCN] $^+$

20 Example 104

3-Amino-5-(3,5-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.03 (1H, d, $J=6.5$ Hz), 4.97 (1H, sept, $J=6.5$ Hz), 6.40 (1H, d, $J=9.5$ Hz), 7.16-7.59 (7H, m), 13.16

25 (1H, brs)

MS (ESI⁺) : 387 [M+H]⁺, 428 [M+H+MeCN]⁺

Example 105

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-
5-phenyl-2-pyrazinecarboxylic acid

5 ¹H-NMR (DMSO-d₆ δ) : 3.42 (3H, s), 6.18 (1H, d, J=9.0 Hz),
7.03 (1H, dd, J=2.8, 9.0 Hz), 7.38-7.53 (7H, m), 7.91 (1H,
d, J=2.5 Hz)

Example 106

A suspension of 3-amino-6-(1-isopropyl-6-oxo-1,6-
10 dihydro-3-pyridyl)-5-(4-methoxyphenyl)-2-
pyrazinecarboxylic acid in 1,2-dichlorobenzene (3 ml) was
heated at 200°C and stirred for 4 hours. This reaction
mixture was cooled to room temperature. To this solution
was added IPE and stirred at room temperature for 1 hour.
15 The precipitate was collected by filtration and washed with
IPE. The residual solid was placed on a column of silica-gel
and eluted with CHCl₃ - MeOH (20 : 1). The eluent was
evaporated and the residue was purified by
recrystallization from EtOH - water to give 5-[5-amino-
20 3-(4-methoxyphenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-
pyridone (88 mg) as a pale brown crystal.

¹H-NMR (DMSO-d₆ δ) : 1.02 (6H, d, J=7.0 Hz), 3.75 (3H, s),
4.94 (1H, sept, J=7.0 Hz), 6.31 (1H, d, J=9.5 Hz), 6.55 (2H,
brs), 6.94 (2H, d, J=9.0 Hz), 7.29-7.42 (4H, m), 7.87 (1H,
25 s)

MS (ESI⁺) : 337 [M+H]⁺, 378 [M+H+MeCN]⁺

The following 24 compounds were obtained in a similar manner to that of Example 106.

Example 107

5 5-[5-Amino-3-(2-methoxyphenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

¹H-NMR (DMSO-d₆ δ) : 0.91 (6H, brs), 3.48 (3H, s), 4.87 (1H, sept, J=6.8 Hz), 6.31 (1H, d, J=9.0 Hz), 6.51 (2H, brs), 6.97-7.10 (3H, m), 7.33-7.51 (3H, m), 7.90 (1H, s)

10 MS (ESI⁺) : 337 [M+H]⁺, 378 [M+H+MeCN]⁺

Example 108

5-[5-Amino-3-(3-methoxyphenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

¹H-NMR (DMSO-d₆ δ) : 0.98 (6H, d, J=7.0 Hz), 3.69 (3H, s),
15 4.92 (1H, sept, J=7.0 Hz), 6.32 (1H, d, J=9.5 Hz), 6.61 (2H, brs), 6.89-6.95 (3H, m), 7.24-7.33 (3H, m), 7.43 (1H, dd, J=2.5, 9.5 Hz), 7.92 (1H, s)

Example 109

20 5-[5-Amino-3-(2-methylphenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

¹H-NMR (DMSO-d₆ δ) : 0.88 (6H, d, J=6.5 Hz), 1.97 (3H, s), 4.84 (1H, sept, J=6.5 Hz), 6.32 (1H, d, J=9.0 Hz), 6.58 (2H, brs), 7.02 (1H, d, J=2.5 Hz), 7.27 (4H, brs), 7.56 (1H, dd, J=2.5, 9.0 Hz), 7.95 (1H, s)

25 Example 110

5-[5-Amino-3-(2,3-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

¹H-NMR(DMSO-d₆ δ) : 0.96 (6H, d, J=7 Hz), 4.91 (1H, sept, J=7 Hz), 6.36 (1H, d, J=9.5 Hz), 6.75 (2H, brs), 7.2 (1H, d, J=2.5 Hz), 7.3-7.51 (4H, m), 8.01 (1H, s)

MS(ESI⁺) : 343[M+H]⁺, 484[M+H+MeCN]⁺

Example 111

5-[5-Amino-3-(2,4-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

10 ¹H-NMR(DMSO-d₆ δ) : 0.97 (6H, d, J=7.0 Hz), 4.92 (1H, t, J=7.0 Hz), 6.35 (1H, d, J=9.0 Hz), 6.7 (2H, brs), 7.19-7.30 (3H, m), 7.47 (1H, dd, J=2.8, 9.0 Hz), 7.56-7.68 (1H, m), 7.97 (1H, s)

MS(ESI⁺) : 343[M+H]⁺, 384[M+H+MeCN]⁺

15 Example 112

5-[5-Amino-3-(2,5-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

¹H-NMR(DMSO-d₆ δ) : 0.97 (6H, d, J=6.8 Hz), 4.91 (1H, sept, J=6.8 Hz), 6.36 (1H, d, J=9.5 Hz), 6.73 (2H, brs), 7.21-7.30 (3H, m), 7.44-7.52 (2H, m), 7.99 (1H, s)

MS(ESI⁺) : 343[M+H]⁺, 384[M+H+MeCN]⁺

Example 113

5-[5-Amino-3-(2-furyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

25 ¹H-NMR(DMSO-d₆ δ) : 1.22 (6H, d, J=7.0 Hz), 5.06 (1H, sept,

J=7.0 Hz), 6.38 (1H, d, J=9.0 Hz), 6.56 (1H, dd, J=1.8, 3.5 Hz), 6.65-6.66 (1H, m), 7.36 (3H, dd, J=2.8, 9.5 Hz), 7.58 (2H, d, J=2.5 Hz), 7.70 (1H, m), 7.87 (1H, s)

MS(ESI⁺) : 297[M+H]⁺, 338[M+H+MeCN]⁺

5 Example 114

5-[5-Amino-3-(3-furyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

¹H-NMR(DMSO-d₆ δ) : 1.19 (6H, d, J=6.5 Hz), 5.04 (1H, sept, J=6.5 Hz), 6.4 (1H, d, J=12.0 Hz), 6.42 (1H, brs), 6.54 (2H, brs), 7.39 (1H, dd, J=2.5, 9.5 Hz), 7.59 (1H, d, J=2.5 Hz), 7.65-7.69 (2H, m), 7.84 (1H, brs)

MS(ESI⁺) : 297[M+H]⁺, 338[M+H+MeCN]⁺

Example 115

15 5-[5-Amino-3-(2-thienyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

¹H-NMR(DMSO-d₆ δ) : 1.20 (6H, d, J=6.5 Hz), 5.06 (1H, sept, J=6.5 Hz), 6.4 (1H, d, J=9.5 Hz), 6.63 (2H, brs), 6.99-7.04 (2H, m), 7.36 (1H, dd, J=2.5, 9.5 Hz), 7.59 (1H, dd, J=2.0, 4.5 Hz), 7.68 (1H, d, J=2.0 Hz), 7.84 (1H, s)

20 MS(ESI⁺) : 313[M+H]⁺, 354[M+H+MeCN]⁺

Example 116

5-[5-Amino-3-(3-thienyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

¹H-NMR(DMSO-d₆ δ) : 1.09 (6H, d, J=6.5 Hz), 4.97 (1H, sept, J=6.5 Hz), 6.35 (1H, d, J=9.5 Hz), 6.56 (2H, brs), 7.04 (1H,

dd, J=1.3, 5.0 Hz), 7.38-7.44 (2H, m), 7.51-7.58 (2H, m),
7.87 (1H, s)

MS(ESI⁺) : 313[M+H]⁺, 354[M+H+MeCN]⁺

Example 117

5 5-[5-Amino-3-(5-methyl-2-thienyl)-2-pyrazinyl]-1-
isopropyl-2(1H)-pyridone

¹H-NMR(DMSO-d₆ δ) : 1.22 (6H, d, J=6.5 Hz), 2.41 (3H, s),
5.07 (1H, sept, J=6.5 Hz), 6.40 (1H, d, J=9.5 Hz), 6.57 (2H,
brs), 6.69-6.70 (1H, m), 6.84 (1H, d, J=3.5 Hz), 7.35 (1H,
10 dd, J=2.5, 9.0 Hz), 7.70 (1H, d, J=2.5 Hz), 7.79 (1H, s)

MS(ESI⁺) : 327[M+H]⁺, 368[M+H+MeCN]⁺

Example 118

5-[5-Amino-3-(1H-pyrazol-4-yl)-2-pyrazinyl]-1-
isopropyl-2(1H)-pyridone

15 ¹H-NMR(DMSO-d₆ δ) : 1.20 (6H, d, J=6.5 Hz), 5.05 (1H, sept,
J=6.5 Hz), 6.38 (1H, d, J=9.0 Hz), 6.45 (2H, brs), 7.34 (1H,
dd, J=2.5, 9.0 Hz), 7.50-7.62 (3H, m), 7.77 (1H, s), 12.92
(1H, brs)

MS(ESI⁺) : 319[M+Na]⁺, 615[2M+Na]⁺

20 Example 119

5-[5-Amino-3-[(E)-2-phenylvinyl]-2-pyrazinyl]-1-
isopropyl-2(1H)-pyridone

¹H-NMR(DMSO-d₆ δ) : 1.30 (6H, d, J=7.0 Hz), 5.13 (1H, sept,
J=7.0 Hz), 6.49 (1H, d, J=9.5 Hz), 6.58 (2H, brs), 7.16 (1H,
25 d, J=15.6 Hz), 7.29-7.40 (3H, m), 7.53-7.65 (4H, m), 7.74

(1H, d, J=2.0 Hz), 7.88 (1H, s)

MS(ESI⁺) : 333[M+H]⁺, 355[M+Na]⁺, 687[2M+Na]⁺

Example 120

5- [5-Amino-3-(4-fluorophenyl)-2-pyrazinyl]-1-methyl-

5 2(1H)-pyridone

¹H-NMR(DMSO-d₆ δ) : 3.40 (3H, s), 6.20 (1H, d, J=9.5 Hz),
6.62 (2H, brs), 7.01 (1H, dd, J=2.5, 9.5 Hz), 7.21 (1H, t,
J=8.5 Hz), 7.46 (1H, dd, J=5.5, 8.5 Hz), 7.74 (1H, d, J=2.5
Hz), 7.90 (1H, s)

10 MS(ESI⁺) : 297[M+H]⁺, 319[M+Na]⁺, 615[2M+Na]⁺

Example 121

5-[5-Amino-3-(2-furyl)-2-pyrazinyl]-1-methyl-2(1H)-
pyridone

¹H-NMR(DMSO-d₆ δ) : 3.46 (3H, s), 6.33 (1H, d, J=9.5 Hz),
15 6.57 (1H, dd, J=1.5, 3.5 Hz), 6.65-6.68 (3H, m), 7.22 (1H,
dd, J=2.5, 9.5 Hz), 7.69 (1H, s), 7.78 (1H, d, J=2.5 Hz),
7.85 (1H, s)

MS(ESI⁺) : 269[M+H]⁺, 291[M+Na]⁺, 559[2M+Na]⁺

Example 122

20 5-[5-Amino-3-(2-thienyl)-2-pyrazinyl]-1-methyl-2(1H)-
pyridone

¹H-NMR(DMSO-d₆ δ) : 3.46 (3H, s), 6.36 (1H, d, J=9.5 Hz),
6.64 (2H, brs), 6.99-7.07 (2H, m), 7.28 (1H, dd, J=2.5, 9.5
Hz), 7.60 (1H, d, J=3.5 Hz), 7.82 (1H, s), 7.85 (1H, d, J=2.5

25 Hz)

MS(ESI⁺) : 307[M+Na]⁺, 591[2M+Na]⁺

Example 123

5-[5-Amino-3-(phenylethynyl)-2-pyrazinyl]-1-isopropyl-
2(1H)-pyridone

5 ¹H-NMR(DMSO-d₆ δ) : 1.26 (6H, d, J=7.0 Hz), 5.06 (1H, t, J=7.0 Hz), 6.49 (1H, d, J=9.5 Hz), 6.75 (2H, brs), 7.43-7.54 (5H, m), 7.91 (1H, dd, J=2.5, 9.5 Hz), 7.95 (1H, s), 8.17 (1H, d, J=2.5 Hz)

MS(ESI⁺) : 331[M+H]⁺, 353[M+Na]⁺, 683[2M+Na]⁺

10 Example 124

5-[5-Amino-3-(2-fluorophenyl)-2-pyrazinyl]-1-isopropyl-
2(1H)-pyridone

¹H-NMR(DMSO-d₆ δ) : 0.92 (6H, d, J=7.0 Hz), 4.88 (1H, sept, J=7.0 Hz), 6.34 (1H, d, J=9.5 Hz), 6.67 (2H, brs), 7.15-7.60 (6H, m), 7.97 (1H, s)

MS(ESI⁺) : 325[M+H]⁺, 366[M+H+MeCN]⁺

Example 125

5-[5-Amino-3-(3-fluorophenyl)-2-pyrazinyl]-1-isopropyl-
2(1H)-pyridone

20 ¹H-NMR(DMSO-d₆ δ) : 1.00 (6H, d, J=6.8 Hz), 4.94 (1H, sept, J=6.8 Hz), 6.35 (1H, d, J=9.0 Hz), 6.68 (2H, brs), 7.28-7.48 (6H, m), 7.95 (1H, s)

MS(ESI⁺) : 341[M+H]⁺, 382[M+H+MeCN]⁺

Example 126

25 5-[5-Amino-3-(3-chlorophenyl)-2-pyrazinyl]-1-isopropyl-

2(1H)-pyridone

¹H-NMR(DMSO-d₆ δ) : 1.00 (6H, d, J=6.8 Hz), 4.94 (1H, sept, J=6.8 Hz), 6.35 (1H, d, J=9.0 Hz), 6.68 (2H, brs), 7.28-7.48 (6H, m), 7.95 (1H, s)

5 MS(ESI⁺) : 341[M+H]⁺, 382[M+H+MeCN]⁺

Example 127

5-[5-Amino-3-(4-chlorophenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

¹H-NMR(DMSO-d₆ δ) : 1.00 (6H, d, J=6.8 Hz), 4.93 (1H, sept, J=6.8 Hz), 6.34 (1H, d, J=9.5 Hz), 6.65 (2H, brs), 7.25 (1H, d, J=2.5 Hz), 7.38-7.48 (5H, m), 7.93 (1H, s)

MS(ESI⁺) : 341[M+H]⁺, 382[M+H+MeCN]⁺

Example 128

5-[5-Amino-3-(3,4-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

¹H-NMR(DMSO-d₆ δ) : 1.03 (6H, d, J=6.8 Hz), 4.96 (1H, sept, J=6.8 Hz), 6.35 (1H, d, J=9.5 Hz), 6.68 (2H, brs), 7.20-7.53 (6H, m), 7.95 (1H, s)

MS(ESI⁺) : 343[M+H]⁺, 384[M+H+MeCN]⁺

20 Example 129

5-[5-Amino-3-(3,5-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

¹H-NMR(DMSO-d₆ δ) : 1.04 (6H, d, J=6.8 Hz), 4.96 (1H, sept, J=6.8 Hz), 6.37 (1H, d, J=9.0 Hz), 6.72 (2H, brs), 7.07-7.46 (5H, m), 7.97 (1H, s)

MS(ESI⁺) : 343[M+H]⁺, 384[M+H+MeCN]⁺

Example 130

5- (5-Amino-3-phenyl-2-pyrazinyl)-1-methyl-2(1H)-
pyridone

5 ¹H-NMR(DMSO-d₆ δ) : 3.38 (3H, s), 6.16 (1H, d, J=4.8 Hz),
6.60 (2H, brs), 6.99 (1H, dd, J=1.4, 4.8 Hz), 7.36-7.42 (5H,
m), 7.72 (1H, d, J=1.4 Hz), 7.90 (1H, s)

Example 131

To a suspension of 3-amino-6-(1-isopropyl-6-oxo-
10 1,6-dihydro-3-pyridyl)-5-(2-pyridyl)-2-
pyrazinecarboxamide (52 mg) in dioxane (0.5 ml) was added
an aq. NaOH (2M, 1 ml) and this solution was heated at 100°C
for 4 hours. This reaction mixture was cooled to room
temperature and the pH of this solution was adjusted to 2.5
15 with 2N aq. HCl. This solution was evaporated under reduced
pressure to give yellow solid. A suspension of this yellow
solid in 1,2-dichlorobenzene (2 ml) was heated at 200°C and
stirred for 4 hours. This reaction mixture was cooled to
room temperature. To this solution was added IPE and stirred
20 at room temperature for 1 hour. The precipitate was
collected by filtration and washed with IPE. The residual
solid was placed on a column of silica-gel and eluted with
CHCl₃ - MeOH - 28% aq. ammonia (15 : 1 : 0.1). The eluent
was evaporated and the residue was purified by
25 recrystallization from EtOAc - IPE to give 5-[5-amino-

3-(2-pyridyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

(5 mg) as a pale yellow crystal.

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.13 (6H, d, $J=7.0$ Hz), 5.18 (1H, t, $J=7.0$ Hz), 6.48 (1H, d, $J=9.0$ Hz), 7.29-7.38 (3H, m), 7.46
5 (1H, d, $J=7.5$ Hz), 7.75 (1H, dt, $J=1.7, 7.5$ Hz), 8.09 (1H, s), 8.71 (1H, d, $J=4.5$ Hz)

MS(ESI $^+$) : 308[M+H] $^+$, 349[M+H+MeCN] $^+$

The following 2 compounds were obtained in a similar manner to that of Example 131.

10 Example 132

5-[5-Amino-3-(3-pyridyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.98 (6H, d, $J=7.0$ Hz), 4.92 (1H, t, $J=7.0$ Hz), 6.35 (1H, d, $J=9.5$ Hz), 6.71 (2H, brs), 7.3 (1H, d, $J=2.5$ Hz), 7.38-7.46 (2H, m), 7.79 (1H, dt, $J=2.5, 4.0$ Hz), 7.97 (1H, s), 8.51 (1H, dd, $J=1.5, 5.0$ Hz), 8.56 (1H, d, $J=1.5$ Hz)

MS(ESI $^+$) : 308[M+H] $^+$, 349[M+H+MeCN] $^+$

Example 133

20 5-[5-Amino-3-(4-pyridyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.96 (6H, d, $J=7.0$ Hz), 4.92 (1H, t, $J=7.0$ Hz), 6.36 (1H, d, $J=9.5$ Hz), 6.74 (2H, brs), 7.25 (1H, d, $J=2.5$ Hz), 7.36-7.48 (3H, m), 7.99 (1H, brs), 8.56-8.59
25 (2H, m)

MS(ESI⁺) : 308[M+H]⁺, 349[M+H+MeCN]⁺

Example 134

3-Amino-5-chloro-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (500 mg),
5 (4-methoxyphenyl)boronic acid (740 mg), and Pd(PPh₃)₄ (56.3 mg) in 2M aq. Na₂CO₃ (3.25 ml) and dioxane (20 ml) was refluxed for 3 hours. Water (40 ml) and EtOAc (30 ml) were poured into the reaction mixture and the aqueous solution was extracted with EtOAc. The organic layer was washed with
10 water and brine, and dried over MgSO₄. After filtration, the solvent was removed under reduced pressure. The residual solid was placed on a column of silica-gel and eluted with CHCl₃ - MeOH (97 : 3). The eluent was evaporated and the residue was suspended with IPE and filtrated to give
15 yellow powder. To a suspension of this yellow powder in dioxane (0.5 ml) was added an aq. NaOH (2M, 1 ml) and this solution was heated at 100°C for 4 hours. This reaction mixture was cooled to room temperature and the pH of this solution was adjusted to 2.5 with 2N aq. HCl. This solution
20 was evaporated under reduced pressure to give yellow solid. A suspension of this yellow solid in 1,2-dichlorobenzen (2 ml) was heated at 200°C and stirred for 4 hours. This reaction mixture was cooled to room temperature. To this solution was added IPE and stirred at room temperature for
25 1 hour. The precipitate was collected by filtration and

washed with IPE. The residual solid was placed on a column of silica-gel and eluted with CHCl_3 - MeOH (97 : 3). The eluent was evaporated and the residue was purified by GPC (Gel Permeation Chromatography) to give 5-[5-amino-3-(5-chloro-2-thienyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (25 mg) and 5-[5-amino-3-(5'-chloro-2,2'-bithien-5-yl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (26 mg) as yellow powder.

5-[5-Amino-3-(5-chloro-2-thienyl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.24 (6H, d, $J=7.0$ Hz), 5.08 (1H, sept, $J=7.0$ Hz), 6.43 (1H, d, $J=9.0$ Hz), 6.7 (2H, brs), 6.86 (1H, d, $J=11.4$ Hz), 7.02 (1H, d, $J=4.0$ Hz), 7.38 (1H, dd, $J=2.5$, 9.0 Hz), 7.77 (1H, d, $J=2.5$ Hz), 7.85 (1H, brs)

MS(ESI $^+$) : 347[M+H] $^+$, 388[M+H+MeCN] $^+$

5-[5-Amino-3-(5'-chloro-2,2'-bithien-5-yl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 1.24 (6H, d, $J=6.5$ Hz), 5.09 (1H, sept, $J=6.5$ Hz), 6.44 (1H, d, $J=9.5$ Hz), 6.69 (2H, brs), 6.93 (1H, d, $J=3.5$ Hz), 7.12-7.21 (3H, m), 7.40 (1H, dd, $J=2.5$, 9.5 Hz), 7.78 (1H, d, $J=2.5$ Hz), 7.85 (1H, s)

MS(ESI $^+$) : 429[M+H] $^+$, 470[M+H+MeCN] $^+$

Example 135

3-Amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-N-methyl-2-pyrazinecarboxamide

The title compound was obtained in a similar manner to that of Preparation 42.

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.98 (6H, d, $J=7.0$ Hz), 2.84 (3H, d, $J=5.0$ Hz), 4.92 (1H, sept, $J=7.0$ Hz), 6.39 (1H, d, $J=9.0$ Hz), 7.21-7.78 (8H, m), 8.68 (1H, d, $J=5.0$ Hz)

MS(ESI $^+$) : 382[M+H] $^+$, 404[M+Na] $^+$, 785[2M+Na] $^+$

Example 136

To a suspension of 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid (350 mg) in MeOH (7.0 ml), was added thionyl chloride (0.146 m) dropwise under ice-bath cooling. After 1 hour stirring at the same temperature, the mixture was allowed to warm to room temperature. The mixture was stirred for 6 hours and then refluxed with stirring for 15 hours. After cooling, the solvent was removed under reduced pressure. Water was poured into the residue and the pH of the mixture was adjusted to 10 with 1N aq. NaOH. A precipitate was isolated by filtration, washed with water, and dried in vacuo to give methyl 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate (244 mg).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.91 (6H, d, $J=6.8$ Hz), 3.89 (3H, s), 4.89 (1H, qq, $J=6.8$, 6.8 Hz), 6.41 (1H, d, $J=9.3$ Hz), 7.21 (1H, d, $J=2.4$ Hz), 7.30-7.50 (7H, m), 7.56 (1H, dd, $J=2.4$, 9.3 Hz)

MS(ESI⁺) : 365[M+H]⁺, 387[M+Na]⁺

Example 137

Under ice-bath cooling, methylmagnesium chloride (3M solution, 0.46 ml) was added to a suspension of methyl
5 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate (100 mg) in THF (10 ml). After 7.5 hours stirring at the same temperature, sat. aq. ammonium chloride solution (1 ml) was poured into the mixture. Water and EtOAc were poured into the mixture and
10 the organic layer was separated, washed with water and brine, and dried over MgSO₄. The solvent was removed under reduced pressure. The residue was recrystallized from MeOH-IPE and dried under reduced pressure to give 5-[5-amino-6-(1-hydroxy-1-methylethyl)-3-phenyl-2-pyrazinyl]-1-
15 isopropyl-2(1H)-pyridone (41 mg).

¹H-NMR(DMSO-d₆ δ) : 0.93 (6H, d, J=6.8 Hz), 1.56 (6H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 5.76 (1H, brs), 6.37 (1H, d, J=9.3 Hz), 6.59 (2H, brs), 7.17 (1H, d, J=2.4 Hz), 7.20-7.50 (5H, m), 7.53 (1H, dd, J=2.4, 9.3 Hz)

20 MS(ESI⁺) : 365[M+H]⁺

Example 138

To a solution of 5-(6-acetyl-5-amino-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (82 mg) in THF - MeOH (1 : 1, 2.0 ml), was added sodium borohydride (8.9 mg).
25 The mixture was stirred at room temperature for 4 hours.

1N HCl (0.05 ml) was poured into the mixture. Water and EtOAc were poured into the mixture and the organic layer was separated, washed with water and brine, and dried over MgSO₄. The solvent was removed under reduced pressure. The residue was purified by column chromatography. The desired product was recrystallized from EtOH and dried in vacuo to give 5-[5-amino-6-(1-hydroxyethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (16 mg).

¹H-NMR(DMSO-d₆ δ) : 0.93 (3H, d, J=6.7 Hz), 0.94 (3H, d, J=6.7 Hz), 1.46 (3H, d, J=6.5 Hz), 4.70-5.00 (2H, m), 5.57 (1H, d, J=5.4 Hz), 6.35 (1H, d, J=9.4 Hz), 6.40 (2H, brs), 7.18 (1H, d, J=2.5 Hz), 7.40 (5H, m), 7.53 (1H, dd, J=2.5, 9.4 Hz)

MS(ESI⁺) : 351[M+H]⁺

15 Example 139

Under ice-bath cooling, NaH (60% pure, 18 mg) was added to a suspension of 5-[5-amino-6-(hydroxymethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (100 mg) in DMF (1.0 ml). After 10 minute stirring, MeI (127 mg) was added to the mixture. After 10 minutes stirring at the same temperature, the mixture was allowed to warm to 25°C. After 3.5 hours stirring, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over MgSO₄. The solvent was removed under reduced pressure and the residue was purified

by column chromatography, triturated with IPE, and dried in vacuo to give 5-[5-amino-6-(methoxymethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (40 mg).

¹H-NMR(DMSO-d₆ δ) : 0.93 (6H, d, J=6.7 Hz), 3.36 (3H, s),
5 4.53 (2H, s), 4.89 (1H, qq, J=6.7, 6.7 Hz), 6.36 (1H, d, J=9.4 Hz), 6.41 (1H, brs), 7.17 (1H, d, J=2.5 Hz), 7.2-7.5 (4H, m), 7.50 (1H, dd, J=2.5, 9.4 Hz)

MS(ESI⁺) : 351[M+H]⁺, 373[M+Na]⁺

Example 140

10 5-{5-Amino-6-[(benzyloxy)methyl]-3-phenyl-2-pyrazinyl}-1-isopropyl-2(1H)-pyridone

The title compound was obtained in a similar manner to that of Preparation 139.

¹H-NMR(DMSO-d₆ δ) : 0.93 (6H, d, J=6.8 Hz), 4.62 (2H, s),
15 4.67 (2H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.35 (1H, d, J=9.4 Hz), 6.45 (2H, brs), 7.18 (1H, d, J=2.4 Hz), 7.20-7.40 (10H, m), 7.49 (1H, dd, J=2.4, 9.4 Hz)

MS(ESI⁺) : 427[M+H]⁺, 449[M+Na]⁺

Example 141

20 Under ice-bath cooling, N-bromosuccinimide (1.83 g) was added to a solution of 5-(5-amino-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (3.0 g) in DMF (90 ml). The mixture was stirred at the same temperature for 2 hours. Water and CH₂Cl₂ were poured into the mixture and
25 the organic layer was separated, washed with sat. aq. sodium

thiosulfate solution, sat. aq. NaHCO₃ solution, water, and brine, and dried over MgSO₄. The solvent was removed under reduced pressure. The residue was purified by column chromatography (silica-gel, toluene - EtOAc),

5 recrystallized from EtOH, and dried in vacuo to give 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (3.0 g).

¹H-NMR(DMSO-d₆ δ) : 0.93 (6H, d, J=6.8 Hz), 4.88 (1H, qq, J=6.8, 6.8 Hz), 6.35 (1H, d, J=9.4 Hz), 6.89 (2H, brs), 7.20
10 (1H, d, J=2.5 Hz), 7.30-7.50 (6H, m)

MS(ESI⁺) : 385[M+H]⁺, 407[M+Na]⁺

Example 142

To a suspension of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg) and
15 Pd(PPh₃)₄ (15 mg) in THF (1.0 ml), was added a solution of methylzinc chloride in THF (2.0M, 0.75 ml). The mixture was stirred at 25°C for 7.5 hours and then heated at 60°C for 1.5 hours. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed
20 with water and brine, and dried over MgSO₄. The solvent was removed under reduced pressure. The residue was crystallized from MeOH - IPE and dried in vacuo to give 5-(5-amino-6-methyl-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (95 mg).

25 ¹H-NMR(DMSO-d₆ δ) : 0.94 (6H, d, J=6.8 Hz), 2.38 (3H, s),

4.89 (1H, qq, J=6.8, 6.8 Hz), 6.33 (1H, d, J=9.4 Hz), 6.38 (2H, s), 7.15 (1H, d, J=2.4 Hz), 7.20-7.50 (5H, m), 7.49 (1H, dd, J=2.4, 9.4 Hz)

MS(ESI⁺) : 321[M+H]⁺, 343[M+Na]⁺

5 Example 143

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg), phenylboronic acid (79 mg), Pd(PPh₃)₄ (9 mg), a solution of Na₂CO₃ (110 mg) in water (0.8 ml) and dioxane (2.0 ml) was heated at 90°C with stirring for 1 hour. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over MgSO₄. The solvent was removed under reduced pressure. The residue was recrystallized from MeOH - IPE and dried in vacuo to give 5-(5-amino-3,6-diphenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (84 mg).

¹H-NMR(DMSO-d₆ δ) : 0.94 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 6.30-6.40 (3H, m), 7.24 (dH, d, J=2.0 Hz), 7.30-7.70 (9H, m), 7.80-7.90 (2H, m)

20 MS(ESI⁺) : 383[M+H]⁺, 405[M+Na]⁺

Example 144

5-[5-Amino-6-(2-furyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

The title compound was obtained in a similar manner to that of Preparation 143.

¹H-NMR(DMSO-d₆ δ) : 0.95 (6H, d, J=6.8 Hz), 4.91 (1H, qq, J=6.8, 6.8 Hz), 6.38 (1H, d, J=9.4 Hz), 6.60-6.80 (3H, m), 7.19 (1H, d, J=3.4 Hz), 7.27 (1H, d, J=2.4 Hz), 7.30-7.50 (5H, m), 7.59 (1H, dd, J=2.4, 9.4 Hz), 7.89 (1H, d, J=1.1

5 Hz)

MS(ESI⁺) : 373[M+H]⁺, 395[M+Na]⁺

Example 145

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg),
10 acrylamide (55 mg), Pd(OAc)₂ (3 mg),
tris(2-methylphenyl)phosphine (8 mg), NEt₃ (0.11 ml), and
DMF (1.0 ml) was heated with stirring at 60°C for 1 hour
and then at 90°C for 5 hours. After cooling, EtOAc and water
were poured into the mixture, and the organic layer was
15 separated, washed with water and brine, and dried over MgSO₄.
The solvent was removed under reduced pressure. The residue
was recrystallized from EtOAc and dried in vacuo to give
(2E)-3-[3-amino-6-(1-isopropyl-6-oxo-
1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinyl]acrylamide
20 (70 mg).

¹H-NMR(DMSO-d₆ δ) : 0.93 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 6.40 (1H, d, J=9.4 Hz), 6.81 (2H, brs), 7.08 (1H, d, J=14.9 Hz), 7.10-7.20 (2H, m), 7.20-7.50 (5H, m), 7.62 (1H, dd, J=2.5, 9.3 Hz), 7.70 (1H, brs), 7.75 (1H, d, J=14.9 Hz)
25

MS (ESI⁺) : 376 [M+H]⁺, 398 [M+Na]⁺

Example 146

(2E)-3-[3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinyl]-N,N-dimethylacrylamide

5 The title compound was obtained in a similar manner to that of Preparation 145.

¹H-NMR(DMSO-d₆ δ) : 0.96 (6H, d, J=6.7 Hz), 2.96 (3H, s),
3.16 (3H, s), 4.92 (1H, qq, J=6.7, 6.7 Hz), 6.36 (1H, d,
J=9.4 Hz), 6.84 (2H, brs), 7.30-7.60 (8H, m), 7.79 (1H, d,
10 J=14.6 Hz)

MS (ESI⁺) : 404 [M+H]⁺, 426 [M+Na]⁺

Example 147

To a mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (500 mg),
15 ethynyl(trimethyl)silane (255 mg), PdCl₂(PPh₃)₂ (46 mg),
CuI (12 mg), and CH₂Cl₂ (10 ml), was added NEt₃ (0.2 ml) under
ice-bath cooling. The mixture was allowed to warm to 25°C
and stirred for 15 hours. Water and EtOAc were poured into
the mixture, and the organic layer was separated, washed
20 with water and brine, and dried over MgSO₄. The solvent was
removed under reduced pressure. The residue was purified
by column chromatography (silica-gel; CH₂Cl₂ - MeOH),
recrystallized from EtOH, and dried in vacuo to give
5-(5-amino-3-phenyl-6-[(trimethylsilyl)ethynyl])-
25 2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (373 mg).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.29 (9H, s), 0.94 (6H, d, $J=6.7$ Hz),
4.89 (1H, qq, $J=6.7$, 6.7 Hz), 6.34 (1H, d, $J=9.4$ Hz), 6.70
(2H, brs), 7.21 (1H, d, $J=2.4$ Hz), 7.30-7.50 (5H, m), 7.47
(1H, dd, $J=2.5$, 9.4 Hz)

5 MS(ESI^+) : 403 $[\text{M}+\text{H}]^+$, 425 $[\text{M}+\text{Na}]^+$

Example 148

A mixture of 5-(5-amino-3-phenyl-
6-[(trimethylsilyl)ethynyl]-2-pyrazinyl)-1-isopropyl-
2(1H)-pyridone (300 mg) and sat. K_2CO_3 in MeOH (4.5 ml) was
10 stirred at 25°C for 3 hours. Water and EtOAc were poured
into the mixture, and the organic layer was separated,
washed with water and brine, and dried over MgSO_4 . The
solvent was removed under reduced pressure. The residue was
purified by short column (silica-gel; CH_2Cl_2) and
15 recrystallized from EtOH to give 5-(5-amino-6-ethynyl-
3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100
mg).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.95 (6H, d, $J=6.8$ Hz), 4.71 (1H, s),
4.89 (1H, qq, $J=6.8$, 6.8 Hz), 6.34 (1H, d, $J=9.3$ Hz), 6.75
20 (2H, brs), 7.22 (1H, d, $J=2.5$ Hz), 7.30-7.50 (6H, m)

MS(ESI^+) : 331 $[\text{M}+\text{H}]^+$, 353 $[\text{M}+\text{Na}]^+$

Example 149

A mixture of 5-(5-amino-6-bromo-3-phenyl-
2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg), sodium
25 methoxide (70 mg), CuI (5 mg) in NMP (1.0 ml) was heated

at 100°C for 2.5 hours. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over MgSO₄. The solvent was removed under reduced pressure. The residue was
5 recrystallized from MeOH - IPE to give 5-(5-amino-6-methoxy-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (58 mg).

¹H-NMR(DMSO-d₆ δ) : 0.94 (6H, d, J=6.7 Hz), 3.98 (3H, s), 4.90 (1H, qq, J=6.7, 6.7 Hz), 6.35 (1H, d, J=9.4 Hz), 6.49
10 (2H, brs), 7.19 (1H, d, J=9.4 Hz), 7.20-7.40 (5H, m), 7.52 (1H, dd, J=2.5, 9.4 Hz)

MS(ESI⁺) : 337[M+H]⁺, 359[M+Na]⁺

Example 150

A mixture of 5-(5-amino-6-methoxy-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (80 mg), conc.
15 HCl (0.8 ml), and dioxane (1.6 ml) was heated with stirring at 100°C for 3 hours. After cooling, the pH of the mixture was adjusted to 8 and a generated precipitate was isolated by filtration and dried in vacuo to give 5-(5-amino-6-hydroxy-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (36 mg).

¹H-NMR(DMSO-d₆ δ) : 1.08 (6H, d, J=6.8 Hz), 4.94 (1H, qq, J=6.8, 6.8 Hz), 6.26 (1H, d, J=9.4 Hz), 6.76 (2H, brs), 7.13 (1H, dd, J=2.2, 9.4 Hz), 7.1-7.3 (5H, m), 7.46 (1H, d, J=2.2
25 Hz), 11.91 (1H, brs)

MS(ESI⁺) : 323[M+H]⁺, 345[M+Na]⁺

Example 151

To a solution of phenol (147 mg) in NMP (1.0 ml), was added 60% NaH (52 mg) under ice-bath cooling. After 5 minutes stirring, 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg) was added to the mixture at the same temperature. And then the mixture was heated at 100°C with stirring for 5.5 hours. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over MgSO₄. The solvent was removed under reduced pressure. The residue was recrystallized from MeOH - IPE to give 5-(5-amino-6-phenoxy-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (88 mg).

¹H-NMR(DMSO-d₆ δ) : 0.90 (6H, d, J=6.8 Hz), 4.86 (1H, qq, J=6.8, 6.8 Hz), 6.23 (1H, d, J=10.1 Hz), 7.15 (2H, m), 7.20-7.50 (10H, m)

MS(ESI⁺) : 399[M+H]⁺, 421[M+Na]⁺

Example 152

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg) and a solution of methylamine in THF (2.0M, 1.0 ml) was heated at 100°C with stirring for 20 hours in a sealed tube. After cooling, the solvent was removed under reduced pressure and the residue was recrystallized from MeOH - IPE to give

5-[5-amino-6-(methylamino)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (13 mg). The filtrate was concentrated in vacuo, and the residue was rinsed with MeOH - IPE to give the desired product (60 mg).

5 $^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.94 (6H, d, $J=6.7$ Hz), 2.93 (3H, d, $J=4.4$ Hz), 4.90 (1H, qq, $J=6.7$, 6.7 Hz), 6.11 (2H, brs), 6.33 (1H, d, $J=9.3$ Hz), 6.49 (1H, m), 7.19 (1H, d, $J=2.4$ Hz), 7.10-7.40 (5H, m), 7.52 (1H, dd, $J=2.4$, 9.4 Hz)
MS(ESI $^+$) : 336[M+H] $^+$, 358[M+Na] $^+$

10 Example 153

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg), morpholine (113 mg), and NMP (1.0 ml) was heated at 150°C with stirring for 1 day. After cooling, EtOAc and water were
15 poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over MgSO $_4$. The solvent was removed under reduced pressure, and the residue was recrystallized from MeOH - IPE and dried in vacuo to give 5-[5-amino-6-(4-morpholinyl)-3-phenyl-
20 2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (84 mg).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.94 (6H, d, $J=6.7$ Hz), 3.10-3.20 (4H, m), 3.70-3.90 (4H, m), 4.90 (1H, qq, $J=6.7$, 6.7 Hz), 6.22 (2H, brs), 6.35 (1H, d, $J=9.4$ Hz), 7.19 (1H, d, $J=2.4$ Hz), 7.20-7.40 (5H, m), 7.54 (1H, dd, $J=2.4$, 9.4 Hz)

25 MS(ESI $^+$) : 392[M+H] $^+$, 414[M+Na] $^+$

Example 154

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg), dimethylamine hydrochloride (106 mg),

5 N,N-diisopropylethylamine (201 mg) in NMP (1.0 ml) was heated at 150°C with stirring for 65 hours. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over MgSO₄. The solvent was removed under reduced

10 pressure. The residue was recrystallized from MeOH - IPE and dried in vacuo to give 5-[5-amino-6-(dimethylamino)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (8 mg).

¹H-NMR(DMSO-d₆ δ) : 0.94 (6H, d, J=7.0 Hz), 2.83 (6H, s), 4.90 (1H, qq, J=7.0, 7.0 Hz), 6.16 (2H, brs), 6.34 (1H, d, J=9.5 Hz), 7.20 (1H, d, J=2.5 Hz), 7.20-7.40 (5H, m), 7.54

15 (1H, dd, J=2.5, 9.5 Hz)

MS(ESI⁺) : 350[M+H]⁺, 372[M+Na]⁺

Example 155

To a solution of pyrazole (106 mg) in NMP (1.0 ml),

20 was added 60% NaH (52 mg) under ice-bath cooling. After 5 minutes stirring, 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg) was added to the mixture. And then the mixture was heated at 100°C with stirring for 2 hours. After cooling, EtOAc and

25 water were poured into the mixture, and the organic layer

was separated, washed with water and brine, and dried over MgSO_4 . The solvent was removed under reduced pressure, and the residue was recrystallized from MeOH and dried in vacuo to give 5-[5-amino-3-phenyl-6-(1H-pyrazol-1-yl)-

5 2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (60 mg).

$^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.98 (6H, d, $J=6.8$ Hz), 4.92 (1H, qq, $J=6.8$, 6.8 Hz), 6.38 (1H, d, $J=9.4$ Hz), 6.68 (1H, m), 7.3-7.5 (6H, m), 7.5-7.7 (3H, m), 7.94 (1H, m), 8.78 (1H, m)

$\text{MS}(\text{ESI}^-)$: 371[M-H] $^-$

10 Example 156

5-[5-amino-3-phenyl-6-(1H-pyrrol-1-yl)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

The title compound was obtained in a similar manner to that of Preparation 155.

15 $^1\text{H-NMR}$ (DMSO- d_6 δ) : 0.95 (6H, d, $J=6.8$ Hz), 4.90 (1H, qq, $J=6.8$, 6.8 Hz), 6.3-6.4 (3H, m), 6.49 (2H, brs), 7.28 (1H, d, $J=2.4$ Hz), 7.30-7.50 (7H, m), 7.53 (1H, dd, $J=2.4$, 9.4 Hz)

$\text{MS}(\text{ESI}^+)$: 372[M+H] $^+$, 394[M+Na] $^+$

20 Example 157

To a suspension of 60% NaH (52 mg) in NMP (1.0 ml), was added thiophenol (143 mg) under ice-bath cooling. After 10 minute stirring, 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1H)-pyridone (100 mg) was

25 added to the mixture at the same temperature. The mixture

was stirred at the same temperature for 10 minutes and then allowed to warm to 25°C. After 2 hours stirring, the mixture was heated at 100°C for 1 hour. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over MgSO₄. The solvent was removed under reduced pressure. The residue was recrystallized from MeOH - IPE to give 5-[5-amino-3-phenyl-6-(phenylthio)-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone (93 mg).

¹H-NMR(DMSO-d₆ δ) : 0.93 (6H, d, J=6.8 Hz), 4.87 (1H, qq, J=6.8, 6.8 Hz), 6.18 (1H, d, J=9.4 Hz), 6.62 (2H, brs), 7.06 (1H, dd, J=2.4, 9.4 Hz), 7.17 (1H, d, J=2.4 Hz), 7.3-7.5 (8H, m), 7.5-7.6 (2H, m)


MS(ESI⁺) : 415[M+H]⁺, 437[M+Na]⁺

15


CLAIMS

1. A pyrazine derivative shown by the following formula

(I):



wherein



wherein

R⁶ is hydrogen, or optionally substituted lower alkyl;

R⁷ is hydrogen or halogen;

15 R⁸ is lower alkyl;

R² is hydrogen; hydroxy; halogen; cyano; or lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, aryloxy, arylthio, acyl, aryl, heterocyclic group or amino, each of which is optionally substituted by

20 substituent(s);


R³ and R⁴ are independently hydrogen, lower alkyl or acyl; and

R⁵ is lower alkyl, lower alkenyl, lower alkynyl, cyano, aryl or heterocyclic group, each of which is

25 optionally substituted by substituent(s);

or a salt thereof.

2. The compound of claim 1, wherein



wherein

R^6 is hydrogen, lower alkyl, aryl(lower)alkyl,
heteroaryl(lower)alkyl;

R^7 is hydrogen or halogen;

10 R^2 is hydrogen, halogen, cyano, optionally substituted
lower alkyl, optionally substituted lower alkynyl,
lower alkoxy, aryloxy, arylthio, carbamoyl,
carboxy, protected carboxy or optionally
substituted amino;

15 R^3 and R^4 are independently hydrogen or lower alkyl;
and

R^5 is aryl or heteroaryl each of which is optionally
substituted by one or more substituent(s);

or a salt thereof.

20 3. The compound of claim 2, wherein

R^2 is hydrogen, halogen, cyano,
hydroxylated(lower)alkyl, lower alkynyl, lower
alkoxy, aryloxy, arylthio, carboxy, esterified
carboxy, carbamoyl, amidated carboxy, amino or
25 mono- or di-(lower)alkylamino;

R³ and R⁴ are independently hydrogen;

R⁵ is aryl or heteroaryl, each of which is optionally substituted by one or more substituent(s) selected from the group consisting of halogen and lower alkoxy;

R⁶ is hydrogen or lower alkyl; and

R⁷ is hydrogen;

or a salt thereof.

4. The compound of claim 3, wherein

R² is hydrogen, bromo, cyano, hydroxymethyl, hydroxyethyl, hydroxypropyl, ethynyl, methoxy, ethoxy, propoxy, phenyloxy, phenylthio, carboxy, carbamoyl, mono- or di-methylaminocarbonyl, pyridylmethylaminocarbonyl, hydroxymethylaminocarbonyl or mono- or di-methylamino;

R³ and R⁴ are independently hydrogen;

R⁵ is phenyl, pyridyl, furyl, thienyl, pyrrolyl or pyrazolyl, each of which is optionally substituted

by one or more substituent(s) selected from the group consisting of fluoro, chloro and methoxy;

R⁶ is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl or *t*-butyl ; and

R⁷ is hydrogen;

or a salt thereof.

5. The compound of claim 4, wherein

R^2 is hydrogen, cyano, ethynyl, methoxy, phenyloxy,
phenylthio, carboxy, carbamoyl or methylamino;
and

5 R^5 is phenyl, furyl or thienyl, each of which is
optionally substituted by one or more
substituent(s) selected from the group consisting
of fluoro, chloro and methoxy;
or a salt thereof.


10 6. The compound of claim 5, wherein

R^2 is hydrogen, cyano, carboxy, carbamoyl or
methylamino;

R^5 is phenyl which is optionally substituted by one or
more fluoro; and

15 R^6 is hydrogen, methyl, ethyl or isopropyl;
or a salt thereof.


7. A process for preparing the pyrazine compound of the
following formula (I):



wherein R^1 , R^2 , R^3 , R^4 and R^5 are each as defined in claim
1, or a salt thereof;

which comprises

25 (1) reacting of a compound of the formula (II):



wherein R^1 , R^2 , R^3 and R^4 are each as defined above, and

5 Hal is a halogen atom;

or a salt thereof,

with a compound of the formula (III) :



wherein

10 R^5 is as defined above, and

Z is hydrogen, an alkali metal (e.g. lithium, sodium, potassium, etc.), SnBu_3 , BW_2 or Met-Hal;

wherein BW_2 is a part of organoboron compound such

as $\text{B}(\text{OH})_2$, $\text{B}(\text{CHCH}_3\text{CH}(\text{CH}_3)_2)_2$,

15 tetramethyl-1,3,2-dioxaborolan-2-yl,

9-borabicyclo[3.3.1]nonanyl, or the like;


and

Met-Hal is a part of metalhalide compound such as

MgBr , ZnCl , or the like;

20 or a salt thereof,


to give a compound of the formula (I):



25 wherein R^1 , R^2 , R^3 , R^4 and R^5 are each as defined above,

or a salt thereof,


(2) hydrolyzing of a compound of the formula (Ia)



wherein R³, R⁴ and R⁵ are each as defined above, and

R⁸ is as defined in claim 1, or a salt thereof,

to give a compound of the formula (Iba):




wherein R³, R⁴ and R⁵ are each as defined above, and

R⁹ is cyano, carbamoyl or carboxy;


or a salt thereof,

15 (3) alkylating to a nitrogen atom of a compound of the formula (Ib):



20 wherein R², R³, R⁴ and R⁵ are each as defined above, or a salt thereof,

with a compound of the formula (IV):



wherein R¹⁰ is lower alkyl, aryl(lower)alkyl or


25 heteroaryl(lower)alkyl, each of which is

optionally substituted by one or more
suitable substituent(s), and

Y is a leaving group;


or a salt thereof,

5 to give a compound of the formula (Ic):



10 wherein R², R³, R⁴, R⁵ and R¹⁰ are each as defined above, or
a salt thereof,


(4) hydrolyzing of a compound of the formula (Id):



15

wherein R¹, R³, R⁴ and R⁵ are each as defined above, or a
salt thereof,

to give a compound of the formula (Ie):




20

wherein R¹, R³, R⁴ and R⁵ are each as defined above, or a
salt thereof,


(5) decarboxylating of a compound (Ie) or a salt thereof

25 above to give a compound of the formula (If):



wherein R^1 , R^3 , R^4 and R^5 are each as defined above, or a
 5 salt thereof,

(6) halogenating of a compound (If) or a salt thereof above
 to give a compound of the formula (Ih):



wherein R^1 , R^3 , R^4 , R^5 and Hal are each as defined above, or
 a salt thereof,

(7) reacting of a compound (Ih) or a salt thereof above
 with a compound of the formula (V):




wherein Z is defined above, and

R^{13} is lower alkyl, lower alkenyl, lower alkynyl,
 lower alkoxy, aryloxy, arylthio, acyl, aryl,
 heterocyclic group or amino, each of which is
 20 optionally substituted by substituent(s);

or a salt thereof,

to give a compound of the formula (Ij):




wherein R^1 , R^3 , R^4 , R^5 and R^{13} are each as defined above,
or a salt thereof,

(8) reacting of a compound of the formula (XI):



wherein R^1 is as defined above, or a salt thereof,
with aminomalonitrile,
to give a compound of the formula (XII):




wherein R^1 and R^2 are each as defined above, or a salt thereof,

(9) halogenating of a compound of the formula (XV):



wherein R^1 , R^2 , R^3 and R^4 are each as defined above, or
a salt thereof,

20 with a compound of the formula (XVI):



wherein Hal is as defined above,

to give a compound (II) or a salt thereof above.

8. A pharmaceutical composition comprising the compound

25 of claim 1 or a pharmaceutically acceptable salt thereof

in admixture with a pharmaceutically acceptable carrier.

9. A method for preventing or treating a disease selected from the group consisting of depression, dementia, Parkinson's disease, anxiety, pain, cerebrovascular disease, heart failure, hypertension, circulatory insufficiency, post-resuscitation, asystole, bradyarrhythmia, electro-mechanical dissociation, hemodynamic collapse, SIRS (systemic inflammatory response syndrome), multiple organ failure, renal failure (renal insufficiency), renal toxicity, nephrosis, nephritis, edema, obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer, pancreatitis, Meniere's syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus, myocardial infarction, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack and angina pectoris, which comprises administering the compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal.
10. A method for preventing or treating a disease selected from the group consisting of depression, dementia, Parkinson's disease, anxiety, pain, cerebrovascular disease, Meniere's syndrome and cerebral infarction,

which comprises administering any of the compound of claim 1 to 7 or a pharmaceutically acceptable salt thereof to a human being or an animal.

11. A method for preventing or treating a disease selected
5 from the group consisting of depression, dementia, Parkinson's disease and anxiety, which comprises administering any of the compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal
- 10 12. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof as a medicament.
13. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof as an adenosine antagonist.
14. Use of the compound of claim 1 or a pharmaceutically
15 acceptable salt thereof as an A₁ receptor and A₂ receptor dual antagonist.
15. A process for preparing a pharmaceutical composition which comprises admixing the compound of claim 1 or a pharmaceutically acceptable salt thereof with a
20 pharmaceutically acceptable carrier.
16. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof for the production of a pharmaceutical composition for the therapy of diseases on which an adenosine antagonist is therapeutically
25 effective.

17. A method for evaluation of adenosine antagonism which comprises use of compound of claim 1 or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP2004/016193

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/04 C07D401/14 C07D409/14 C07D405/14 A61K31/4965

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 1 308 441 A (EISAI CO., LTD) 7 May 2003 (2003-05-07) examples 103a; 103b, 182, 183; table page 55, compounds 3-8, table page 60, compounds 112-114; table page 63, compounds 154-156 & WO 02/14282 A (EISAI CO., LTD; HARADA, HITOSHI; ASANO, OSAMU; MIYAZAWA, SHUHEI; UEDA,) 21 February 2002 (2002-02-21) cited in the application	1-17
Y	WO 00/25791 A (SMITHKLINE BEECHAM CORPORATION; ADAMS, JERRY, L; BOEHM, JEFFREY, C; HA) 11 May 2000 (2000-05-11) overlap; claims; pages 5, 11 and 26 -/-	1-17

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *G* document member of the same patent family

Date of the actual completion of the international search

17 March 2005

Date of mailing of the international search report

24/03/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP2004/016193

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01/60806 A (NEUROGEN CORPORATION; YOON, TAEYOUNG; GE, PING; HORVATH, RAYMOND, F; D) 23 August 2001 (2001-08-23) overlap; pages 1-2; table I page 46, examples 3,10,14; table II page 55, example 46o-c, page 57, example 46j-k, page 59, examples 47m-n; table III page 74, examples 62z	1-17
Y	WO 03/045924 A (PHARMACIA & UPJOHN COMPANY; VERHOEST, PATRICK, R; HOFFMAN, ROBERT, L;) 5 June 2003 (2003-06-05) overlap; pages 6, 73 and 74	1-17
Y	WO 01/62233 A (F. HOFFMANN LA ROCHE AG) 30 August 2001 (2001-08-30) abstract; claims	1-17
A,P	WO 2004/016605 A (FUJISAWA PHARMACEUTICAL CO., LTD; AKAHANE ATSUSHI) 26 February 2004 (2004-02-26) the whole document	1-17
A	US 4 072 746 A (LESHER ET AL) 7 February 1978 (1978-02-07) abstract; claims	1-17
A	US 4 313 951 A (LESHER ET AL) 2 February 1982 (1982-02-02) abstract; claims	1-17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2004/016193

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCTASA/ 210

Continuation of Box II.1

Although claims 9-14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claim 17 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP2004/016193

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1308441	A	07-05-2003	AU 7774101 A CA 2417846 A1 EP 1308441 A1 MX PA03001136 A NO 20030637 A US 2004006082 A1 CN 1446202 A WO 0214282 A1 ZA 200300482 A	25-02-2002 30-01-2003 07-05-2003 24-06-2003 10-04-2003 08-01-2004 01-10-2003 21-02-2002 10-05-2004
WO 0214282	A	21-02-2002	AU 7774101 A CA 2417846 A1 CN 1446202 A EP 1308441 A1 WO 0214282 A1 MX PA03001136 A NO 20030637 A US 2004006082 A1 ZA 200300482 A	25-02-2002 30-01-2003 01-10-2003 07-05-2003 21-02-2002 24-06-2003 10-04-2003 08-01-2004 10-05-2004
WO 0025791	A	11-05-2000	AT 258055 T AU 1909200 A DE 69914357 D1 DE 69914357 T2 EP 1126852 A1 ES 2212657 T3 JP 2002528506 T WO 0025791 A1 US 2004014973 A1 US 6548503 B1	15-02-2004 22-05-2000 26-02-2004 11-11-2004 29-08-2001 16-07-2004 03-09-2002 11-05-2000 22-01-2004 15-04-2003
WO 0160806	A	23-08-2001	AU 3849401 A BG 106968 A BR 0108363 A CA 2398937 A1 CN 1400970 A CZ 20022739 A3 EE 200200453 A EP 1255740 A2 EP 1500653 A1 HR 20020747 A2 HU 0301573 A2 JP 2004500383 T MX PA02007868 A NO 20023869 A SK 11542002 A3 WO 0160806 A2 US 2003018035 A1 ZA 200206103 A	27-08-2001 30-04-2003 10-02-2004 23-08-2001 05-03-2003 12-02-2003 15-12-2003 13-11-2002 26-01-2005 31-12-2004 29-12-2003 08-01-2004 10-02-2003 11-09-2002 04-03-2003 23-08-2001 23-01-2003 20-08-2003
WO 03045924	A	05-06-2003	AU 2002343557 A1 BR 0214309 A CA 2467870 A1 EP 1446387 A1 WO 03045924 A1 US 2003144297 A1 US 2005049257 A1	10-06-2003 13-10-2004 05-06-2003 18-08-2004 05-06-2003 31-07-2003 03-03-2005

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/JP2004/016193

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0162233	A	30-08-2001	AU 5464301 A	03-09-2001
			BR 0108611 A	06-05-2003
			CA 2398274 A1	30-08-2001
			CN 1438890 A	27-08-2003
			CZ 20023199 A3	14-05-2003
			WO 0162233 A2	30-08-2001
			EP 1261327 A2	04-12-2002
			HR 20020673 A2	31-12-2004
			HU 0300029 A2	28-05-2003
			JP 2003523380 T	05-08-2003
			MX PA02008240 A	29-11-2002
			NO 20024006 A	22-08-2002
			NZ 520241 A	28-05-2004
			US 2001027196 A1	04-10-2001
			ZA 200206077 A	30-10-2003
WO 2004016605	A	26-02-2004	WO 2004016605 A1	26-02-2004
US 4072746	A	07-02-1978	US 4004012 A	18-01-1977
			AR 220512 A1	14-11-1980
			AR 223137 A1	31-07-1981
			AR 231541 A1	28-12-1984
			AT 362375 B	11-05-1981
			AT 4380 A	15-10-1980
			AT 357534 B	10-07-1980
			AT 48979 A	15-12-1979
			AT 359494 B	10-11-1980
			AT 767476 A	15-04-1980
			AU 1857376 A	20-04-1978
			BE 847196 A1	13-04-1977
			CA 1089860 A1	18-11-1980
			CA 1103253 A2	16-06-1981
			CA 1103254 A2	16-06-1981
			CH 620908 A5	31-12-1980
			CH 619936 A5	31-10-1980
			CH 618969 A5	29-08-1980
			DE 2646469 A1	28-04-1977
			DK 203583 A ,B,	06-05-1983
			DK 455876 A ,B,	15-04-1977
			ES 452405 A1	01-11-1977
			FI 762919 A ,B,	15-04-1977
			FI 65061 B	30-11-1983
			FR 2327779 A1	13-05-1977
			GB 1512129 A	24-05-1978
			GR 64513 A1	09-04-1980
			IE 43956 B1	15-07-1981
			IL 50632 A	30-11-1979
			LU 76011 A1	25-05-1977
			MX 6821 E	06-08-1986
			MX 7114 E	29-06-1987
			NL 7611394 A ,B,	18-04-1977
			NO 763480 A ,B,	15-04-1977
			NO 771952 A ,B,	15-04-1977
			NO 813710 A ,B,	15-04-1977
			NZ 182270 A	28-07-1978
			PH 12507 A	18-04-1979
			PH 20254 A	10-11-1986
			PT 65708 A ,B	01-11-1976

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP2004/016193

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4072746 A		SE 430335 B	07-11-1983
		SE 7611376 A	22-06-1977
		SE 441744 B	04-11-1985
		SE 8102022 A	30-03-1981
		US 4225715 A	30-09-1980
		US 4107315 A	15-08-1978
		US 4137233 A	30-01-1979
		US 4199586 A	22-04-1980
		ZA 7606042 A	28-09-1977
US 4313951 A	02-02-1982	AT 379387 B	27-12-1985
		AT 578080 A	15-05-1985
		CA 1143736 A1	29-03-1983
		CA 1155852 A2	25-10-1983
		CH 649535 A5	31-05-1985
		DE 3044568 A1	27-08-1981
		DK 501180 A ,B,	27-05-1981
		EG 14983 A	31-12-1985
		ES 8302661 A1	16-04-1983
		ES 8301920 A3	01-04-1983
		FI 803652 A ,B,	27-05-1981
		FI 854740 A ,B,	29-11-1985
		FR 2470124 A1	29-05-1981
		FR 2553767 A1	26-04-1985
		GB 2065642 A ,B	01-07-1981
		GB 2131421 A ,B	20-06-1984
		GR 71608 A1	17-06-1983
		HK 31189 A	21-04-1989
		HK 83090 A	19-10-1990
		IE 50632 B1	28-05-1986
		IL 61501 A	29-06-1984
		IL 69847 A	29-06-1984
		IT 1148740 B	03-12-1986
		KR 8500025 B1	11-02-1985
		KR 8500317 B2	20-03-1985
		KR 8500632 B2	06-05-1985
		LU 82957 A1	04-06-1981
		MX 158257 A	18-01-1989
		NL 970028 I1	01-10-1997
		NL 8006399 A ,B,	16-06-1981
		NO 803550 A ,B,	27-05-1981
		NO 854001 A	27-05-1981
		NO 156127 B	21-04-1987
		NZ 195564 A	30-09-1983
		PH 22629 A	28-10-1988
		PT 72106 A ,B	01-12-1980
		SE 442398 B	23-12-1985
		SE 8008252 A	27-05-1981
		US 4365065 A	21-12-1982
		AT 379386 B	27-12-1985
		AT 95983 A	15-05-1985
		AU 551627 B2	08-05-1986
		AU 2475384 A	05-07-1984
		AU 536354 B2	03-05-1984
		AU 6455780 A	04-06-1981
		BE 886336 A1	25-05-1981
		JP 1639011 C	31-01-1992
		JP 2050903 B	05-11-1990

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/JP2004/016193

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4313951	A	JP 60214776 A	28-10-1985
		JP 1391523 C	23-07-1987